WO2024068705A1 - Polypeptides activés par une protéase - Google Patents

Polypeptides activés par une protéase Download PDF

Info

Publication number
WO2024068705A1
WO2024068705A1 PCT/EP2023/076655 EP2023076655W WO2024068705A1 WO 2024068705 A1 WO2024068705 A1 WO 2024068705A1 EP 2023076655 W EP2023076655 W EP 2023076655W WO 2024068705 A1 WO2024068705 A1 WO 2024068705A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
protease
activatable
seq
amino acid
Prior art date
Application number
PCT/EP2023/076655
Other languages
English (en)
Inventor
Laura CODARRI DEAK
Greta DURINI
Linda FAHRNI
Anne Freimoser-Grundschober
Ralf Hosse
Christian Klein
Ekkehard Moessner
Valeria NICOLINI
Pablo Umaña
Inja Waldhauer
Original Assignee
F. Hoffmann-La Roche Ag
Hoffmann-La Roche Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag, Hoffmann-La Roche Inc. filed Critical F. Hoffmann-La Roche Ag
Publication of WO2024068705A1 publication Critical patent/WO2024068705A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Definitions

  • the present invention generally relates to novel protease-activated polypeptides, particularly interleukin-2 (IL-2) polypeptides. More particularly, the invention concerns protease-activated IL-2 polypeptides that exhibit improved properties for use as immunotherapeutic agents. In addition, the invention relates to protease-activated IL-2 polypeptides or immunoconjugates, polynucleotides, vectors and host cells comprising such vectors or polynucleotide molecules. The invention further relates to methods for producing the protease-activated IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
  • IL-2 interleukin-2
  • the selective destruction of an individual target cell or a specific target cell type is often desirable in a variety of clinical settings. For example, it is a primary goal of cancer therapy to specifically destroy tumor cells, while leaving healthy cells and tissues intact and undamaged.
  • NK natural killer
  • CTLs cytotoxic T lymphocytes
  • conjugates designed to bind to a surface antigen on target cells and comprising interleukin-2 (IL-2) variants are supposed to activate nearby T effector cells and NK cells.
  • IL-2 interleukin-2
  • the simultaneous binding of such an conjugate to its target and the interleukin-2 receptor will cause activation of T effector cells and NK cells in the proximity of the target (in trans) or when the target is expressed on the T effector cell and NK cell, this cell is activated upon binding (in cis).
  • Interleukin-2 also known as T cell growth factor (TCGF)
  • TCGF T cell growth factor
  • TCGF T cell growth factor
  • IL-2 mediates its action by binding to IL-2 receptors (IL-2R), which consist of up to three individual subunits, the different association of which can produce receptor forms that differ in their affinity to IL-2.
  • IL-2R IL-2 receptors
  • Association of the a (CD25), P (CD122), and y (y c , CD132) subunits results in a trimeric, high-affinity receptor for IL-2.
  • Dimeric IL-2 receptor consisting of the P and y subunits is termed intermediate-affinity IL-2R.
  • the a subunit forms the monomeric low affinity IL-2 receptor.
  • the dimeric intermediate-affinity IL-2 receptor binds IL-2 with approximately 100-fold lower affinity than the trimeric high-affinity receptor
  • both the dimeric and the trimeric IL-2 receptor variants are able to transmit signal upon IL-2 binding
  • the a-subunit, CD25 is not essential for IL- 2 signalling. It confers high-affinity binding to its receptor, whereas the P subunit, CD 122, and the y-subunit are crucial for signal transduction (Krieg et al., Proc Natl Acad Sci 107, 11906-11 (2010)).
  • Trimeric IL-2 receptors including CD25 are expressed by (resting) CD4 + forkhead box P3 (FoxP3) + regulatory T (Treg) cells. They are also transiently induced on conventional activated T cells, whereas in the resting state these cells express only dimeric IL-2 receptors. Treg cells consistently express the highest level of CD25 in vivo (Fontenot et al., Nature Immunol 6, 1142- 51 (2005)).
  • IL-2 is synthesized mainly by activated T-cells, in particular CD4 + helper T cells. It stimulates the proliferation and differentiation of T cells, induces the generation of cytotoxic T lymphocytes (CTLs) and the differentiation of peripheral blood lymphocytes to cytotoxic cells and lymphokine-activated killer (LAK) cells, promotes cytokine and cytolytic molecule expression by T cells, facilitates the proliferation and differentiation of B-cells and the synthesis of immunoglobulin by B-cells, and stimulates the generation, proliferation and activation of natural killer (NK) cells (reviewed e.g. in Waldmann, Nat Rev Immunol 6, 595-601 (2009); Olejniczak and Kasprzak, Med Sci Monit 14, RA179-89 (2008); Malek, Annu Rev Immunol 26, 453-79 (2008)).
  • CTLs cytotoxic T lymphocytes
  • LAK lymphokine-activated killer
  • IL-2 has a dual function in the immune response in that it not only mediates expansion and activity of effector cells, but also is crucially involved in maintaining peripheral immune tolerance.
  • AICD IL-2 induced activation-induced cell death
  • T cells A major mechanism underlying peripheral self-tolerance is IL-2 induced activation-induced cell death (AICD) in T cells.
  • AICD is a process by which fully activated T cells undergo programmed cell death through engagement of cell surface-expressed death receptors such as CD95 (also known as Fas) or the TNF receptor.
  • CD95 also known as Fas
  • FasL Fas ligand
  • TNF tumor necrosis factor
  • IL-2 is also involved in the maintenance of peripheral CD4 + CD25 + regulatory T (T reg ) cells (Fontenot et al., Nature Immunol 6, 1142-51 (2005); D’Cruz and Klein, Nature Immunol 6, 1152-59 (2005); Maloy and Powrie, Nature Immunol 6, 1171-72 (2005), which are also known as suppressor T cells. They suppress effector T cells from destroying their (self-)target, either through cell-cell contact by inhibiting T cell help and activation, or through release of immunosuppressive cytokines such as IL-10 or TGF-p. Depletion of Treg cells was shown to enhance IL-2 induced anti-tumor immunity (Imai et al., Cancer Sci 98, 416-23 (2007)).
  • IL-2 is not optimal for inhibiting tumor growth, because in the presence of IL-2 either the CTLs generated might recognize the tumor as self and undergo AICD or the immune response might be inhibited by IL-2 dependent Treg cells.
  • VLS vascular leak syndrome
  • VLS Low-dose IL-2 regimens have been tested in patients to avoid VLS, however, at the expense of suboptimal therapeutic results.
  • VLS was believed to be caused by the release of proinflammatory cytokines, such as tumor necrosis factor (TNF)-a from IL-2-activated NK cells, however it has recently been shown that IL-2-induced pulmonary edema resulted from direct binding of IL-2 to lung endothelial cells, which expressed low to intermediate levels of functional aPy IL-2 receptors (Krieg et al., Proc Nat Acad Sci USA 107, 11906-11 (2010)).
  • TNF tumor necrosis factor
  • 2007/0036752 have substituted three residues of IL-2 (Asp20Thr, Asn88Arg, and Glnl26Asp) that contribute to affinity for the intermediate-affinity IL-2 receptor to reduce VLS.
  • Gillies et al. (WO 2008/0034473) have also mutated the interface of IL-2 with CD25 by amino acid substitution Arg38Trp and Phe42Lys to reduce interaction with CD25 and activation of Treg cells for enhancing efficacy.
  • Wittrup et al. (WO 2009/061853) have produced IL-2 mutants that have enhanced affinity to CD25, but do not activate the receptor, thus act as antagonists.
  • the mutations introduced were aimed at disrupting the interaction with the P- and/or y-subunit of the receptor.
  • a particular mutant IL-2 polypeptide designed to overcome the above-mentioned problems associated with IL-2 immunotherapy (toxicity caused by the induction of VLS, tumor tolerance caused by the induction of AICD, and immunosuppression caused by activation of Treg cells), is described in WO 2012/107417.
  • Substitution of the phenylalanine residue at position 42 by alanine, the tyrosine residue at position 45 by alanine and the leucine residue at position 72 of IL-2 by glycine essentially abolishes binding of this mutant IL-2 polypeptide to the a-subunit of the IL-2 receptor (CD25).
  • IL-2 immunotherapy may be improved by selectively targeting IL-2 to tumors, e.g. in the form of immunoconjugates comprising an antibody that binds to an antigen expressed on tumor cells or that binds to effector cells in the tumor environment.
  • immunoconjugates comprising an antibody that binds to an antigen expressed on tumor cells or that binds to effector cells in the tumor environment.
  • IL-2 has been the first effective cancer immunotherapy used to treat metastatic melanoma and renal cell carcinoma.
  • IL-2 at high concentrations, is toxic by inducing vascular leak syndrome (VLS) and detrimentally expands regulatory T cells and induces activation induced cell death due to binding to CD25.
  • VLS vascular leak syndrome
  • IL-2v variants with abolished CD25 binding have been described.
  • cis-targeting of PDl-IL2v to appropriate antigen specific T- cell subsets, together with PD-1/-L1 inhibition is a better way to exploit endogenous immunity therapeutically and one of the strongest immunomodulatory pathway known for unleashing endogenous immunity for cancer immunotherapy.
  • the IL2v moiety to trigger IL-2R signaling in the periphery also for PDl-IL2v not the maximally desired dose can be administered due to the peripheral non-tumor specific IL-2R activation.
  • the therapeutic index is believed to remain narrow with an anticipated MTD with a flat dose of >10- 30 mg in man which may limit utilizing full pathway potential.
  • CD8 T cells could be targeted instead, as well as other T cell targets.
  • Serine proteases e.g. matriptase
  • cysteine proteases e.g. cathepsin S
  • matrix metalloproteinases e.g. MMP-2 and MMP-9
  • Matriptase, matrix metalloproteinase 2 (MMP-2, gelatinase A) and matrix metalloproteinase 9 (MMP-9, gelatinase B) are overexpressed e.g. in breast- and ovarian carcinoma (McGowan, P. M. & Duffy, M. J.
  • MMP-2 and MMP-9 activity was detected in cervical, breast and ovarian carcinoma and ascites of patients with epithelial ovarian cancer (EOC) but not in the serum of these patients (Demeter, A. et al. Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer. Anticancer Res. 25, 2885-2889 (2005)). While matriptase can be detected in normal epithelial cells, matriptase activity is mainly detected in cancer (LeBeau, A. M. et al. Imaging a functional tumorigenic biomarker in the transformed epithelium. Proc. Natl. Acad. Sci. USA 110, 93-98 (2013)).
  • IL-2 variants and conjugates suitable for treatment provides several technical challenges related to efficacy, toxicity, applicability and produceability that have to be met.
  • the conjugate targets an antigen on a target cell, e.g., a cancer cell, that is also expressed in non-target tissue, toxicity can occur.
  • a target cell e.g., a cancer cell
  • toxicity can occur.
  • the present invention is based, in part, on the recognition that tumor environments (TME) highly express proteases compared to normal tissue and that a masked therapeutic agent, preferably protease-activatable interleukin-2, has a reduced or abolished systemic activity and full activity in the tumor environment upon activation by proteases.
  • TAE tumor environments
  • a masked therapeutic agent preferably protease-activatable interleukin-2
  • a first aspect of the invention provides a protease-activatable interleukin-2 (IL-2) polypeptide comprising (i) an IL-2 polypeptide, (ii) a masking moiety and (iii) a linker comprising a first protease cleavage site, wherein the linker has a length of 20 to 45 amino acids, wherein the masking moiety is covalently attached to the IL-2 polypeptide through the linker, wherein the masking moiety is capable of binding to the IL-2 polypeptide thereby reversibly concealing the IL-2 polypeptide, wherein the masking moiety comprises a second protease cleavage site, wherein the masking moiety does not conceal the IL-2 polypeptide upon cleavage at the first and/or the second protease cleavage site.
  • IL-2 interleukin-2
  • the linker has a length of 22 to 43 amino acids. In one embodiment, the linker has a length of 25 to 38 amino acids. In one embodiment, the linker has a length of 25 amino acids, preferably the linker has the sequence according to SEQ ID NO: 64 or SEQ ID NO: 66. In one embodiment, the linker has a length of 38 amino acids, preferably the linker has a sequence according to SEQ ID NO: 63 or SEQ ID NO: 65.
  • the masking moiety is covalently attached to the aminoterminus or carboxy-terminus of the interleukin-2 polypeptide through the linker. In one embodiment, the masking moiety is an IL-2 antagonist.
  • the masking moiety is an IL-2 antibody or an IL-2 receptor subunit.
  • the IL-2 antibody comprises a Fab molecule.
  • the masking moiety is an antibody derived from MT204, preferably MT204.
  • the MT204 antibody is disclosed e.g. in Volkland et al., Molecular Immunology 44 (2007) 1743-1753, and PCT-publication WO 2006/128690 AL More preferably, the masking moiety is a de-immunized MT204-derived binder.
  • the Fab molecule is a single-chain Fab molecule.
  • the second protease cleavage site is located between the variable domain of the heavy chain (VH) and the variable domain of the light chain (VL) of the single-chain Fab molecule.
  • the first protease cleavage site and the second protease cleavage site each comprise at least one protease recognition sequence.
  • the protease recognition sequence of the first protease cleavage site and/or the protease recognition sequence of the second protease cleavage site is either YAARKGGI according to SEQ ID NO:60 and/or PQARK according to SEQ ID NO:61.
  • the IL-2 polypeptide is a wild-type IL-2, preferably a human IL-2 according to SEQ ID NO: 62, or a mutant IL-2 polypeptide.
  • the mutant IL-2 polypeptide comprises any amino acid substitution selected from the group T3A, F42A, Y45A, L72G, C125A of human IL-2 according to SEQ ID NO:62.
  • the mutant IL-2 polypeptide comprises the amino acid substitutions F42A, Y45A and L72G of human IL-2 according to SEQ ID NO:62.
  • the mutant IL-2 polypeptide comprises the amino acid substitutions T3A, F42A, Y45A, L72G and C125A of human IL-2 according to SEQ ID NO:62.
  • the protease-activatable IL-2 polypeptide comprises the amino acid sequence of SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO: 30.
  • the IL-2 polypeptide is further attached to a non-IL-2 moiety.
  • the IL-2 polypeptide shares a carboxy-terminal peptide bond with the masking moiety and an amino-terminal peptide bond with the non-IL-2 moiety or the IL-2 polypeptide shares an aminoterminal peptide bond with the masking moiety and a carboxy-terminal peptide bond with the non-IL-2 moiety.
  • the non-IL-2 moiety is an antigen binding moiety or an effector cell binding moiety.
  • the invention provides an immunoconjugate comprising a protease- activatable IL-2 polypeptide as described herein and an antigen binding moiety and/or an effector cell binding moiety.
  • the protease-activatable IL-2 polypeptide shares an amino- or carboxy-terminal peptide bond with the antigen binding moiety or the effector cell binding moiety.
  • the immunoconjugate comprises a first and a second antigen binding moiety or a first and a second effector cell antigen binding moiety or an antigen binding moiety and an effector cell binding moiety.
  • the protease- activatable IL-2 polypeptide shares an amino- or carboxy-terminal peptide bond with said first antigen binding moiety and said second antigen binding moiety shares an amino- or carboxy- terminal peptide bond with either a) said protease-activatable IL-2 polypeptide or b) said first antigen binding moiety;
  • the protease-activatable IL-2 polypeptide shares an amino- or carboxy-terminal peptide bond with said first effector cell binding moiety and said second effector cell binding moiety shares an amino- or carboxy-terminal peptide bond with either a) said protease-activatable IL-2 polypeptide or b) said first effector cell binding moiety;
  • the protease-activatable IL-2 polypeptide shares an amino- or carboxy-terminal peptide bond with the antigen binding moiety and the effector cell binding moiety shares an amino- or carboxy- terminal peptid
  • the antigen binding moiety or the effector cell binding moiety comprised in the protease-activatable IL-2 polypeptide as disclosed herein or the immunoconjugate as disclosed herein is an antibody or an antibody fragment.
  • the antigen binding moiety and/or said effector cell binding moiety is a Fab molecule or scFv molecule.
  • the antigen binding moiety and/or said effector cell binding moiety is an immunoglobulin molecule, particularly an IgG molecule.
  • the antigen binding moiety is directed to an antigen presented on a tumor cell or in a tumor cell environment and/or wherein said effector cell binding moiety is directed to an effector cell present in a tumor cell environment in order to achieve cis-targeting.
  • the immunoconjugate comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 5, an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 22, and an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 23; (ii) the immunoconjugate comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 5, an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 22, and an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 24; (iii) the immunoconjugate comprises an amino acid sequence that is at
  • the immunoconjugate comprises an amino acid sequence according to SEQ ID NO: 5, an amino acid sequence according to SEQ ID NO: 22, and an amino acid sequence according to SEQ ID NO: 23;
  • the immunoconjugate comprises an amino acid sequence according to SEQ ID NO: 5, an amino acid sequence according to SEQ ID NO: 22, and an amino acid sequence according to SEQ ID NO: 24;
  • the immunoconjugate comprises an amino acid sequence according to SEQ ID NO: 5, an amino acid sequence according to SEQ ID NO: 22, and an amino acid sequence according to SEQ ID NO: 25; or
  • the immunoconjugate comprises an amino acid sequence according to SEQ ID NO: 5, an amino acid sequence according to SEQ ID NO: 22, and an amino acid sequence according to SEQ ID NO: 26.
  • the invention further provides one or more isolated polynucleotide encoding the protease- activatable IL-2 polypeptide as described herein or the immunoconjugate as described herein, one or more expression vectors comprising the polynucleotide as described herein, one or more host cells comprising the polynucleotide as described herein or the expression vector as described herein.
  • Also provided is a method of producing a protease-activatable IL-2 polypeptide or an immunoconjugate as described herein comprising culturing the host cell as described herein under conditions suitable for the expression of the protease-activatable IL-2 polypeptide or the immunoconjugate.
  • protease-activatable IL-2 polypeptide or immunoconjugate as described herein produced by the method described herein.
  • a pharmaceutical composition comprising the protease-activatable IL-2 polypeptide or immunoconjugate as disclosed herein and a pharmaceutically acceptable carrier.
  • the invention encompasses a proteaseactivatable IL-2 polypeptide or an immunoconjugate as described herein for use in the treatment of a disease in an individual in need thereof.
  • said disease is cancer.
  • the individual is a human.
  • protease-activatable IL-2 polypeptide or immunoconjugate as described herein for manufacture of a medicament for treating a disease in an individual in need thereof.
  • a method of treating a disease in an individual comprising administering to said individual a therapeutically effective amount of a composition comprising the protease-activatable IL-2 polypeptide or immunoconjugate as described herein in a pharmaceutically acceptable form.
  • Said disease preferably is cancer.
  • FIG. 1A-I IgG antibodies generated to assess the de-immunized MT204 masks and anti-PDl binder variants by SPR and respective antigens and parental controls.
  • Fig.lA P1AH2050- P1AH2052
  • Fig.lB P1AH4157-P1AH4161
  • Fig.lC P1AI0356-P1AI0360
  • Fig.lD P1AI1648-P1AI1652
  • Fig.lE P1AF7506) One- armed parental MT204 in human IgG PG LALA format
  • Fig.lF IgG antibodies generated to assess the de-immunized MT204 masks and anti-PDl binder variants by SPR and respective antigens and parental controls.
  • Figure 2A-F Human PD1 -targeted masked IL2v constructs with PQARK or YAARKGGI matriptase sites and respective non-masked PD1 -targeted or FAP -targeted controls.
  • Fig.lA (P1AI4322) Bivalent human PDl-targeted human IgG PG LALA with masked IL2v (‘in-line’) fused to the C-terminus of the Fc knob chain, 2 PQARK matriptase sites for the release of the mask and a 38 amino acid linker between the IL2v cytokine and the scFv mask;
  • Fig.lB (P1AI4323) Bivalent human PDl-targeted human IgG PG LALA with masked IL2v (‘in-line’) fused to the C-terminus of the Fc knob chain, 2 PQARK matriptase sites for the release of the mask and a 25 amino acid linker between the IL2v cytokine and the scFv mask;
  • Fig.2C (P1AI4324) Bivalent human PDl-targeted human IgG PG LALA with masked IL2v (‘in-
  • FIG.3A Human PDl-targeted masked IL2v constructs as non-cleavable controls and respective non-masked control.
  • Fig.3A Bivalent human PDl-targeted human IgG PG LALA with masked IL2v (‘in-line’) fused to the C-terminus of the Fc knob chain, a 38 amino acid linker between the IL2v cytokine and the scFv mask, and without matriptase release sites (non-cleavable control);
  • Fig.3B P1AI4647 Bivalent human PDl-targeted human IgG PG LALA with masked IL2v (‘in-line’) fused to the C-terminus of the Fc knob chain, a 25 amino acid linker between the IL2v cytokine and the scFv mask, and without matriptase release sites (non-cleavable control);
  • Fig.3A P1AI
  • Figure 4A-B Murine surrogates of human PDl-targeted masked IL2v constructs with YAARKGGI matriptase sites and respective control.
  • Fig.4A (P1AI4650) Bivalent human PDl- targeted murine IgG DA PG with masked IL2v (‘in-line’) fused to the C-terminus of the Fc DD- chain and 2 YAARKGGI matriptase sites for the release of the mask
  • Fig.4B (P1AI4651) Bivalent human PDl-targeted murine IgG DA PG with masked IL2v (‘in-line’) fused to the C- terminus of the Fc DD- chain and without matriptase release sites (non-cleavable control).
  • Fig.5A shows blockade with P1AH4159, P1AH4160 and P1AH4161.
  • Fig.5B shows blockade with P1AH4157 and P1AH4158.
  • FIG. 6A-B Binding of de-immunized aPD-1 to CD3/CD28 activated CD4 T cells, in comparison to aPD-1 IgG PG LALA, PDl-IL2v and FAP-IL2v.
  • PD1 antibody constructs were added to activated CD4 T cells at different concentrations and the dose-dependent response was measured by flow cytometry. Data were analyzed using GraphPad Prism software (mean ⁇ SEM). Data from 2 donors.
  • Fig.6A shows binding with P1AH4159, P1AH4160 and P1AH4161.
  • Fig.6B shows binding with P1AH4157 and P1AH4158.
  • FIG. 7A-B Binding of de-immunized aPD-1 to CD3/CD28 activated CD4 T cells, in comparison to aPD-1 IgG PG LALA, PDl-IL2v and FAP-IL2v.
  • PD1 antibody constructs were added to activated CD4 T cells at different concentrations and the dose-dependent response was measured by flow cytometry. Data were analyzed using GraphPad Prism software (mean ⁇ SEM). Data from 2 donors.
  • Fig.7A shows binding with P1AH4159, P1AH4160 and P1AH4161.
  • Fig.7B shows binding with P1AH4157 and P1AH4158.
  • FIG. 8A-B Minimal Mixed Lymphocytes Reaction.
  • the effect of several anti-PD-1 blocking antibodies on the increase of allospecific T cell effector function was investigated by depicting the frequencies of Granzyme B production in proliferating CD4 T cells. Data were acquired by flow cytometry and analyzed using GraphPad Prism software (mean ⁇ SEM). Data from 1 experiment (CD4 T cells from 2 donors and mDCs from 2 donors).
  • Fig.8A shows Granzyme B production upon exposure to P1AH4159, P1AH4160 and P1AH4161.
  • Fig.8B shows Granzyme B production upon exposure to P1AH4157 and P1AH4158.
  • FIG. 9A-B Minimal Mixed Lymphocytes Reaction.
  • the effect of several anti-PD-1 blocking antibodies on the increase of allospecific T cell effector function was investigated by depicting the frequencies of Interferon-y production in proliferating CD4 T cells. Data were acquired by flow cytometry and analyzed using GraphPad Prism software (mean ⁇ SEM). Data from 1 experiment (CD4 T cells from 2 donors and mDCs from 2 donors).
  • Fig.9A shows Interferon-y production upon exposure to P1AH4159, P1AH4160 and P1AH4161.
  • Fig.9B shows Interferon-y production upon exposure to P1AH4157 and P1AH4158.
  • Figure 10. Binding of de-immunized PDl-IgGs to human PD1 overexpressing CHO cells was determined by flow cytometry. Molecules were detected with a fluorescently labeled anti-human Fc specific secondary antibody.
  • Blocking of IL2v activity with de-immunized MT204 masks compared to the parental mask was determined by measuring proliferation of human NK92 cells using CellTiter Gio.
  • Figure 12A-B Binding of the indicated TA PDl-IL2v constructs to human PD1 overexpressing CHO cells was determined by flow cytometry. Molecules were detected with a fluorescently labeled anti-human Fc specific secondary antibody.
  • Fig.llA relates to constructs with the PQARK cleavage sites.
  • Fig.llB relates to constructs with the YAARKGGI cleavage sites.
  • Figure 13A-F Proliferation of KHYG-1 cells induced by a set of TA PDl-IL2v constructs was measured using CellTiter Gio.
  • Fig.l3A and Fig.l3B relate to constructs with the PQARK cleavage site.
  • Fig.l3C and Fig.l3D relate to constructs with the YARKGGI cleavage site.
  • Fig.l3E and Fig.l3F relate to constructs without cleavage site.
  • FIG. 14 Results of an efficacy experiment with TA-PDl-IL2v cleavable (YAARKGGI 38mer linker) and non-cleavable Mabs as single agents are presented.
  • the MCA205 fibrosarcoma carcinoma cell line was injected subcutaneously in Black 6-huPDl tg mice to study tumor growth inhibition in a subcutaneous model. Tumor size was measured using a caliper. Therapy started when tumors reached 150 mm 3 .
  • the amount of antibodies injected per mouse was 2 mg/kg for TA-PDl-IL2v YAARKGGI 38mer cleavable and TA-PDl-IL2v non-cleavable given twice a week. The treatment lasted 1 week.
  • the TA-PD-IL2v YAARKGGI 38mer mediated superior efficacy in terms of tumor growth inhibition compared to vehicle and non-cleavable Mab single agent groups
  • FIG. 16A-C Murine surrogates of human PD1 -targeted masked IL2v constructs with and without PQARK matriptase sites.
  • Fig. l6A (P1AK3638) Bivalent human PDl-targeted murine IgG DA PG with masked IL2v (‘in-line’) fused to the C-terminus of the Fc DD- chain and 2 PQARK matriptase sites for the release of the mask;
  • Fig. l6A (P1AK3638) Bivalent human PDl-targeted murine IgG DA PG with masked IL2v (‘in-line’) fused to the C-terminus of the Fc DD- chain and 2 PQARK matriptase sites for the release of the mask;
  • Fig. l6A (P1AK3638) Bivalent human PDl-targeted murine IgG DA PG with masked
  • l6B (P1AK3649) Bivalent human PD1 -targeted murine IgG DA PG with masked IL2v (‘in-line’) fused to the C-terminus of the Fc DD- chain and without matriptase release sites (non-cleavable control).
  • Fig,16C (P1AG7552) Bivalent human PD1 -targeted murine IgG DA PG with IL2v fused to the C-terminus of the Fc DD- chain (non-masked control).
  • FIG. 17A-D Murine surrogates of murine PD1 -targeted masked IL2v constructs with and without PQARK matriptase sites and control IgG.
  • Fig. l7A (P1AK3641) Bivalent murine PD1- targeted murine IgG DA PG with masked IL2v (‘in-line’) fused to the C-terminus of the Fc DD- chain and 2 PQARK matriptase sites for the release of the mask
  • Fig.l7B (P1AK3640) Bivalent murine PDl-targeted murine IgG DA PG with masked IL2v (‘in-line’) fused to the C-terminus of the Fc DD- chain and without matriptase release sites (non-cleavable control);
  • Fig. l7A (P1AK3641) Bivalent murine PD1- targeted murine IgG DA PG with
  • l7C (P1AD4006) Murine PDl-targeted murine IgG used as non-IL2v-fused control construct.
  • Fig. 17D (P1AG9991) Bivalent murine PDl-targeted murine IgG DA PG with IL2v fused to the C- terminus of the Fc DD- chain (non-masked control).
  • FIG 18A-B HEK blue IL2 reporter cell assay with HEK blue IL2 cells overexpressing human PD1 to test activity of murinized TA PDl-IL2v constructs. Constructs were predigested with recombinant human Matripatase (Fig.18 A). Constructs were tested without predigestion (Fig.l8B).
  • FIG 19A-B HEK blue IL2 reporter cell assay with HEK blue IL2 cells overexpressing mouse PD1 to test activity of murinized TA PDl-IL2v constructs containing a mouse specific PD1 binder. Constructs were predigested with recombinant human Matriptase (Fig. l9A). Constructs were tested without predigestion (Fig.l9B).
  • Figure 20A-B Proliferation of NK cells (Fig.20A) and CD8 T cells (Fig.20B) measured by CFSE dilution upon treatment with TA PDl-IL2v constructs that were digested with recombinant human Matriptase.
  • Figure 21A-B Activation of NK cells (Fig.21A) and CD8 T cells (Fig.21B) measured by CD25 upregulation upon treatment with TA PDl-IL2v constructs that were digested with recombinant human Matriptase.
  • FIG 22 Presents the results of an efficacy experiment with TA-PDl-IL2v cleavable (PQARK 25mer linker), non-cleavable and Pembrolizumab Mabs as single agents.
  • the MCA205 fibrosarcoma carcinoma cell line was injected subcutaneously in Black 6-huPDl tg mice to study tumor growth inhibition in a subcutaneous model. Tumor size was measured using a caliper. Therapy started when tumors reached 200 mm 3 .
  • the amount of antibodies injected per mouse was 1 and 3 mg/kg for TA-PDl-IL2v PQARK 25mer cleavable and 3 mg/kg for Pembrolizumab and TA-PDl-IL2v non-cleavable given twice a week. The treatment lasted 1 week.
  • the TA-PD- IL2v PQARK 25mer mediated superior efficacy in terms of tumor growth inhibition compared to vehicle, Pembrolizumab and non-cleavable Mabs single agent groups.
  • FIG. 23 Presents the results of an efficacy experiment with muTA-PDl-IL2v cleavable (PQARK 25mer linker) and muPDl Mabs as single agents.
  • the GL261 glioblastoma cell line was injected subcutaneously in Black 6 mice to study tumor growth inhibition in a subcutaneous model. Tumor size was measured using a caliper. Therapy started when tumors reached 100 mm 3 .
  • the amount of antibodies injected per mouse was 1 and 3 mg/kg for muTA-PDl-IL2v PQARK 25mer cleavable and 3 mg/kg for muPDl given twice a week. The treatment lasted 1 week.
  • the mu-TA-PD-IL2v PQARK 25mer mediated superior efficacy in terms of tumor growth inhibition compared to vehicle and muPDl Mabs single agent groups.
  • Figure 24 Presents the results of an efficacy experiment evaluating TA-PDl-IL2v and FOLR1- TCB Mabs in combination.
  • the BC004 human breast carcinoma PDX cells were injected subcutaneously in humanized NSG mice to study tumor growth inhibition in a breast subcutaneous xenograft model.
  • the amount of antibodies injected per mouse in mg/kg is the following: 1 mg/kg TA-PDl-IL2v PQARK 25mer cleavable linker, 0.1 mg/kg PDl-IL2v non masked, 1 mg/kg Pembrolizumab and 0.3 mg/kg FOLR1-TCB Mabs.
  • the antibodies were injected iv once weekly for 4 weeks.
  • interleukin-2 refers to any native IL-2 from any vertebrate source, including mammals such as primates (e.g. humans) and rodents (e.g., mice and rats), unless otherwise indicated.
  • the term encompasses unprocessed IL-2 as well as any form of IL-2 that results from processing in the cell.
  • the term also encompasses naturally occurring variants of IL-2, e.g. splice variants or allelic variants.
  • the amino acid sequence of an exemplary human IL-2 is shown in SEQ ID NO: 62.
  • IL-2 mutant or "mutant IL-2 polypeptide” as used herein is intended to encompass any mutant forms of various forms of the IL-2 molecule including full-length IL-2, truncated forms of IL-2 and forms where IL-2 is linked to another molecule such as by fusion or chemical conjugation.
  • Full-length when used in reference to IL-2 is intended to mean the mature, natural length IL-2 molecule.
  • full-length human IL-2 refers to a molecule that has 133 amino acids (see e.g. SEQ ID NO: 62).
  • the various forms of IL-2 mutants are characterized in having a at least one amino acid mutation affecting the interaction of IL-2 with CD25.
  • an IL-2 mutant may be referred to herein as an IL-2 mutant peptide sequence, an IL-2 mutant polypeptide, IL-2 mutant protein or IL-2 mutant analog.
  • Designation of various forms of IL-2 is herein made with respect to the sequence shown in SEQ ID NO: 62.
  • Various designations may be used herein to indicate the same mutation.
  • a mutation from phenylalanine at position 42 to alanine can be indicated as 42A, A42, A42, F42A, or Phe42Ala.
  • a “wild-type” form of IL-2 is a form of IL-2 that is otherwise the same as the mutant IL-2 polypeptide except that the wild-type form has a wild-type amino acid at each amino acid position of the mutant IL-2 polypeptide.
  • the wild-type form of this mutant is full-length native IL-2.
  • the IL-2 mutant is a fusion between IL-2 and another polypeptide encoded downstream of IL-2 (e.g.
  • the wild-type form of this IL-2 mutant is IL-2 with a wild-type amino acid sequence fused to the same downstream polypeptide. Furthermore, if the IL-2 mutant is a truncated form of IL-2 (the mutated or modified sequence within the non-truncated portion of IL-2) then the wild-type form of this IL-2 mutant is a similarly truncated IL-2 that has a wild-type sequence.
  • wild-type encompasses forms of IL-2 comprising one or more amino acid mutation that does not affect IL-2 receptor binding compared to the naturally occurring, native IL-2, such as e.g. a substitution of cysteine at a position corresponding to residue 125 of human IL-2 to alanine.
  • wild-type IL-2 for the purpose of the present invention comprises the amino acid substitution C125A.
  • the wild-type IL-2 polypeptide to which the mutant IL-2 polypeptide is compared comprises the amino acid sequence of SEQ ID NO: 62.
  • CD25 or “a-subunit of the IL-2 receptor” as used herein, refers to any native CD25 from any vertebrate source, including mammals such as primates (e.g. humans) and rodents (e.g., mice and rats), unless otherwise indicated.
  • the term encompasses “full-length”, unprocessed CD25 as well as any form of CD25 that results from processing in the cell.
  • the term also encompasses naturally occurring variants of CD25, e.g. splice variants or allelic variants.
  • CD25 is human CD25.
  • high-affinity IL-2 receptor refers to the heterotrimeric form of the IL- 2 receptor, consisting of the receptor y-subunit (also known as common cytokine receptor y- subunit, y c , or CD132), the receptor P-subunit (also known as CD122 or p70) and the receptor a- subunit (also known as CD25 or p55).
  • intermediate-affinity IL-2 receptor refers to the IL-2 receptor including only the y-subunit and the P-subunit, without the a-subunit (for a review see e.g. Olejniczak and Kasprzak, Med Sci Monit 14, RA179-189 (2008)).
  • Treg cell By “regulatory T cell” or “Treg cell” is meant a specialized type of CD4 + T cell that can suppress the responses of other T cells.
  • Treg cells are characterized by expression of the a-subunit of the IL-2 receptor (CD25) and the transcription factor forkhead box P3 (FOXP3) (Sakaguchi, Annu Rev Immunol 22, 531-62 (2004)) and play a critical role in the induction and maintenance of peripheral self-tolerance to antigens, including those expressed by tumors.
  • Treg cells require IL-2 for their function and development and induction of their suppressive characteristics.
  • effector cells refers to a population of lymphocytes that mediate the cytotoxic effects of IL-2. Effector cells include effector T cells such as CD8 + cytotoxic T cells, NK cells, lymphokine-activated killer (LAK) cells and macrophages/monocytes.
  • effector T cells such as CD8 + cytotoxic T cells, NK cells, lymphokine-activated killer (LAK) cells and macrophages/monocytes.
  • LAK lymphokine-activated killer
  • macrophages/monocytes macrophages/monocytes.
  • antigen binding molecule refers in its broadest sense to a molecule that specifically binds an antigenic determinant. Examples of antigen binding molecules are immunoglobulins and derivatives, e.g., fragments, thereof.
  • bispecific means that the antigen binding molecule is able to specifically bind to at least two distinct antigenic determinants.
  • a bispecific antigen binding molecule comprises two antigen binding sites, each of which is specific for a different antigenic determinant.
  • the bispecific antigen binding molecule is capable of simultaneously binding two antigenic determinants, particularly two antigenic determinants expressed on two distinct cells.
  • valent denotes the presence of a specified number of antigen binding sites in an antigen binding molecule.
  • monovalent binding to an antigen denotes the presence of one (and not more than one) antigen binding site specific for the antigen in the antigen binding molecule.
  • an “antigen binding site” refers to the site, i.e. one or more amino acid residues, of an antigen binding molecule which provides interaction with the antigen.
  • the antigen binding site of an antibody comprises amino acid residues from the complementarity determining regions (CDRs).
  • CDRs complementarity determining regions
  • a native immunoglobulin molecule typically has two antigen binding sites, a Fab molecule typically has a single antigen binding site.
  • an antigen binding moiety refers to a polypeptide molecule that specifically binds to an antigenic determinant.
  • an antigen binding moiety is able to direct the entity to which it is attached (e.g., a second antigen binding moiety) to a target site, for example to a specific type of tumor cell or tumor stroma bearing the antigenic determinant.
  • an antigen binding moiety is able to activate signaling through its target antigen, for example a T cell receptor complex antigen.
  • Antigen binding moieties include antibodies and fragments thereof as further defined herein. Particular antigen binding moieties include an antigen binding domain of an antibody, comprising an antibody heavy chain variable region and an antibody light chain variable region.
  • the antigen binding moieties may comprise antibody constant regions as further defined herein and known in the art.
  • Useful heavy chain constant regions include any of the five isotypes: a, 5, a, y, or p.
  • Useful light chain constant regions include any of the two isotypes: K and X.
  • antigenic determinant is synonymous with “antigen” and “epitope,” and refers to a site (e.g., a contiguous stretch of amino acids or a conformational configuration made up of different regions of non-contiguous amino acids) on a polypeptide macromolecule to which an antigen binding moiety binds, forming an antigen binding moiety-antigen complex.
  • Useful antigenic determinants can be found, for example, on the surfaces of tumor cells, on the surfaces of virus-infected cells, on the surfaces of other diseased cells, on the surface of immune cells, free in blood serum, and/or in the extracellular matrix (ECM).
  • ECM extracellular matrix
  • the proteins referred to as antigens herein can be any native form of the proteins from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated.
  • the antigen is a human protein.
  • the term encompasses the “full-length”, unprocessed protein as well as any form of the protein that results from processing in the cell.
  • the term also encompasses naturally occurring variants of the protein, e.g., splice variants or allelic variants.
  • an antigen binding moiety to bind to a specific antigenic determinant can be measured either through an enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to one of skill in the art, e.g., surface plasmon resonance (SPR) technique (analyzed on a BIAcore instrument) (Liljeblad et al., Glyco J 17, 323-329 (2000)), and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)).
  • ELISA enzyme-linked immunosorbent assay
  • SPR surface plasmon resonance
  • the extent of binding of an antigen binding moiety to an unrelated protein is less than about 10% of the binding of the antigen binding moiety to the antigen as measured, e.g., by SPR.
  • an antigen binding moiety that binds to the antigen, or an antigen binding molecule comprising that antigen binding moiety has a dissociation constant (KD) of ⁇ 1 pM, ⁇ 100 nM, ⁇ 10 nM, ⁇ 1 nM, ⁇ 0.1 nM, ⁇ 0.01 nM, or ⁇ 0.001 nM (e.g., 10' 8 M or less, e.g., from 10' 8 M to 10' 13 M, e.g., from 10' 9 M to 10’ 13 M).
  • KD dissociation constant
  • Binding affinity refers to intrinsic binding affinity which reflects a 1: 1 interaction between members of a binding pair (e.g., an antigen binding moiety and an antigen, or a receptor and its ligand).
  • the affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD), which is the ratio of dissociation and association rate constants (koir and k on , respectively).
  • affinities may comprise different rate constants, as long as the ratio of the rate constants remains the same.
  • Affinity can be measured by well-established methods known in the art, including those described herein.
  • a particular method for measuring affinity is Surface Plasmon Resonance (SPR).
  • Reduced binding for example reduced binding to an Fc receptor, refers to a decrease in affinity for the respective interaction, as measured for example by SPR.
  • the term includes also reduction of the affinity to zero (or below the detection limit of the analytic method), i.e. complete abolishment of the interaction.
  • increased binding refers to an increase in binding affinity for the respective interaction.
  • T cell activation refers to one or more cellular response of a T lymphocyte, particularly a cytotoxic T lymphocyte, selected from: proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, and expression of activation markers.
  • target cell antigen refers to an antigenic determinant presented on the surface of a target cell, for example a cell in a tumor such as a cancer cell or a cell of the tumor stroma.
  • first and second with respect to antigen binding moieties etc., are used for convenience of distinguishing when there is more than one of each type of moiety. Use of these terms is not intended to confer a specific order or orientation of the protease-activatable IL-2 polypeptides or immunoconjugates unless explicitly so stated.
  • a “Fab molecule” refers to a protein consisting of the VH and CHI domain of the heavy chain (the “Fab heavy chain”) and the VL and CL domain of the light chain (the “Fab light chain”) of an immunoglobulin.
  • TA tumor-activatable.
  • OA two-armed.
  • fused is meant that the components (e.g., a Fab molecule and an Fc domain subunit) are linked by peptide bonds, either directly or via one or more peptide linkers.
  • single-chain refers to a molecule comprising amino acid monomers linearly linked by peptide bonds.
  • one of the antigen binding moieties is a single-chain Fab molecule, i.e. a Fab molecule wherein the Fab light chain and the Fab heavy chain are connected by a peptide linker to form a single peptide chain.
  • Another term is singlechain variable fragments (scFv).
  • scFv singlechain variable fragments
  • the C-terminus of the Fab light chain is connected to the N-terminus of the Fab heavy chain in the single-chain Fab molecule.
  • crossover Fab molecule also termed “Crossfab” is meant a Fab molecule wherein either the variable regions or the constant regions of the Fab heavy and light chain are exchanged, i.e. the crossover Fab molecule comprises a peptide chain composed of the light chain variable region and the heavy chain constant region, and a peptide chain composed of the heavy chain variable region and the light chain constant region.
  • the peptide chain comprising the heavy chain constant region is referred to herein as the “heavy chain” of the crossover Fab molecule.
  • the peptide chain comprising the heavy chain variable region is referred to herein as the “heavy chain” of the crossover Fab molecule.
  • a “conventional” Fab molecule is meant a Fab molecule in its natural format, i.e. comprising a heavy chain composed of the heavy chain variable and constant regions (VH-CH1), and a light chain composed of the light chain variable and constant regions (VL-CL).
  • VH-CH1 heavy chain variable and constant regions
  • VL-CL light chain variable and constant regions
  • immunoglobulin molecule refers to a protein having the structure of a naturally occurring antibody.
  • immunoglobulins of the IgG class are heterotetrameric glycoproteins of about 150,000 daltons, composed of two light chains and two heavy chains that are disulfide-bonded.
  • each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CHI, CH2, and CH3), also called a heavy chain constant region.
  • VH variable region
  • CHI variable heavy domain
  • CH2 constant domain
  • CL constant light
  • the heavy chain of an immunoglobulin may be assigned to one of five types, called a (IgA), 5 (IgD), 8 (IgE), y (IgG), or p (IgM), some of which may be further divided into subtypes, e.g., yi (IgGi), 72 (IgG?), 73 (IgGs), 74 (IgG4), ai (IgAi) and a? (IgA?).
  • the light chain of an immunoglobulin may be assigned to one of two types, called kappa (K) and lambda (X), based on the amino acid sequence of its constant domain.
  • K kappa
  • X lambda
  • antibody herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, and antibody fragments so long as they exhibit the desired antigen-binding activity.
  • antibody fragment refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds.
  • antibody fragments include but are not limited to Fv, Fab, Fab', Fab’-SH, F(ab')2, diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv), and single-domain antibodies.
  • scFv single-chain antibody molecules
  • Diabodies are antibody fragments with two antigenbinding sites that may be bivalent or bispecific.
  • Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody.
  • a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see e.g., U.S. Patent No. 6,248,516 Bl).
  • Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g., E. coli or phage), as described herein.
  • an antigen binding domain refers to the part of an antibody that comprises the area which specifically binds to and is complementary to part or all of an antigen.
  • An antigen binding domain may be provided by, for example, one or more antibody variable domains (also called antibody variable regions).
  • an antigen binding domain comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).
  • variable region refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen.
  • the variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). See, e.g., Kindt et al., Kuby Immunology, 6 th ed., W.H. Freeman and Co., page 91 (2007).
  • a single VH or VL domain may be sufficient to confer antigen-binding specificity.
  • hypervariable region refers to each of the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops (“hypervariable loops”).
  • native four-chain antibodies comprise six HVRs; three in the VH (Hl, H2, H3), and three in the VL (LI, L2, L3).
  • HVRs generally comprise amino acid residues from the hypervariable loops and/or from the complementarity determining regions (CDRs), the latter being of highest sequence variability and/or involved in antigen recognition. With the exception of CDR1 in VH, CDRs generally comprise the amino acid residues that form the hypervariable loops.
  • Hypervariable regions are also referred to as “complementarity determining regions” (CDRs), and these terms are used herein interchangeably in reference to portions of the variable region that form the antigen binding regions.
  • CDRs complementarity determining regions
  • This particular region has been described by Kabat et al., U.S. Dept, of Health and Human Services, Sequences of Proteins of Immunological Interest (1983) and by Chothia et al., J Mol Biol 196:901-917 (1987), where the definitions include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or variants thereof is intended to be within the scope of the term as defined and used herein.
  • Kabat et al. also defined a numbering system for variable region sequences that is applicable to any antibody.
  • One of ordinary skill in the art can unambiguously assign this system of "Kabat numbering" to any variable region sequence, without reliance on any experimental data beyond the sequence itself.
  • Kabat numbering refers to the numbering system set forth by Kabat et al., U.S. Dept, of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). Unless otherwise specified, references to the numbering of specific amino acid residue positions in an antibody variable region are according to the Kabat numbering system.
  • polypeptide sequences of the sequence listing are not numbered according to the Kabat numbering system. However, it is well within the ordinary skill of one in the art to convert the numbering of the sequences of the Sequence Listing to Kabat numbering.
  • FR Framework or "FR” refers to variable domain residues other than hypervariable region (HVR) residues.
  • the FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1 L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
  • the “class” of an antibody or immunoglobulin refers to the type of constant domain or constant region possessed by its heavy chain.
  • the heavy chain constant domains that correspond to the different classes of immunoglobulins are called a, 5, a, y, and p, respectively.
  • Fc region herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region.
  • the term includes native sequence Fc regions and variant Fc regions.
  • a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain.
  • antibodies produced by host cells may undergo post-translational cleavage of one or more, particularly one or two, amino acids from the C-terminus of the heavy chain.
  • an antibody produced by a host cell by expression of a specific nucleic acid molecule encoding a full-length heavy chain may include the full-length heavy chain, or it may include a cleaved variant of the full-length heavy chain.
  • This may be the case where the final two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, EU numbering system). Therefore, the C-terminal lysine (Lys447), or the C-terminal glycine (Gly446) and lysine (Lys447), of the Fc region may or may not be present.
  • a heavy chain including an Fc region as specified herein, comprised in an antibody according to the invention comprises an additional C-terminal glycine-lysine dipeptide (G446 and K447, EU numbering system).
  • a heavy chain including an Fc region as specified herein, comprised in an antibody according to the invention comprises an additional C-terminal glycine residue (G446, numbering according to EU index).
  • a “subunit” of an Fc domain as used herein refers to one of the two polypeptides forming the dimeric Fc domain, i.e. a polypeptide comprising C-terminal constant regions of an immunoglobulin heavy chain, capable of stable self-association.
  • a subunit of an IgG Fc domain comprises an IgG CH2 and an IgG CH3 constant domain.
  • fused is meant that the components (e.g. a Fab molecule and an Fc domain subunit) are linked by peptide bonds, either directly or via one or more peptide linkers.
  • a “modification promoting the association of the first and the second subunit of the Fc domain” is a manipulation of the peptide backbone or the post-translational modifications of an Fc domain subunit that reduces or prevents the association of a polypeptide comprising the Fc domain subunit with an identical polypeptide to form a homodimer.
  • a modification promoting association as used herein particularly includes separate modifications made to each of the two Fc domain subunits desired to associate (i.e. the first and the second subunit of the Fc domain), wherein the modifications are complementary to each other so as to promote association of the two Fc domain subunits.
  • a modification promoting association may alter the structure or charge of one or both of the Fc domain subunits so as to make their association sterically or electrostatically favorable, respectively.
  • (hetero)dimerization occurs between a polypeptide comprising the first Fc domain subunit and a polypeptide comprising the second Fc domain subunit, which might be non-identical in the sense that further components fused to each of the subunits (e.g., antigen binding moi eties) are not the same.
  • the modification promoting association comprises an amino acid mutation in the Fc domain, specifically an amino acid substitution.
  • the modification promoting association comprises a separate amino acid mutation, specifically an amino acid substitution, in each of the two subunits of the Fc domain.
  • effector functions refers to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype.
  • antibody effector functions include: Clq binding and complement dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), cytokine secretion, immune complex-mediated antigen uptake by antigen presenting cells, down regulation of cell surface receptors (e.g., B cell receptor), and B cell activation.
  • engine engineered, engineering
  • engineering includes modifications of the amino acid sequence, of the glycosylation pattern, or of the side chain group of individual amino acids, as well as combinations of these approaches.
  • the term "immunoconjugate” refers to a polypeptide molecule that includes at least one IL-2 moiety and at least one antigen binding moiety or effector cell binding moiety.
  • the immunoconjugate comprises at least one IL-2 moiety, and at least two antigen binding moieties or at least two effector cell binding moieties.
  • Particular immunoconjugates according to the invention essentially consist of one IL-2 moiety and two antigen binding moieties joined by one or more linker sequences.
  • the antigen binding moiety can be joined to the IL-2 moiety by a variety of interactions and in a variety of configurations as described herein.
  • immunoconjugates according to the invention essentially consist of one IL-2 moiety and two effector cell binding moieties joined by one or more linker sequences.
  • the effector cell binding moiety can be joined to the IL-2 moiety by a variety of interactions and in a variety of configurations as described herein.
  • amino acid mutation as used herein is meant to encompass amino acid substitutions, deletions, insertions, and modifications. Any combination of substitution, deletion, insertion, and modification can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., reduced binding to an Fc receptor, or increased association with another peptide.
  • Amino acid sequence deletions and insertions include amino- and/or carboxy-terminal deletions and insertions of amino acids.
  • Particular amino acid mutations are amino acid substitutions.
  • non-conservative amino acid substitutions i.e. replacing one amino acid with another amino acid having different structural and/or chemical properties, are particularly preferred.
  • Amino acid substitutions include replacement by non-naturally occurring amino acids or by naturally occurring amino acid derivatives of the twenty standard amino acids (e.g., 4- hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine).
  • Amino acid mutations can be generated using genetic or chemical methods well known in the art. Genetic methods may include site-directed mutagenesis, PCR, gene synthesis and the like. It is contemplated that methods of altering the side chain group of an amino acid by methods other than genetic engineering, such as chemical modification, may also be useful. Various designations may be used herein to indicate the same amino acid mutation. For example, a substitution from proline at position 329 of the Fc domain to glycine can be indicated as 329G, G329, G329, P329G, or Pro329Gly.
  • polypeptide refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds).
  • polypeptide refers to any chain of two or more amino acids, and does not refer to a specific length of the product.
  • peptides, dipeptides, tripeptides, oligopeptides, "protein,” “amino acid chain,” or any other term used to refer to a chain of two or more amino acids are included within the definition of "polypeptide,” and the term “polypeptide” may be used instead of, or interchangeably with any of these terms.
  • polypeptide is also intended to refer to the products of post-expression modifications of the polypeptide, including without limitation glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, or modification by non-naturally occurring amino acids.
  • a polypeptide may be derived from a natural biological source or produced by recombinant technology, but is not necessarily translated from a designated nucleic acid sequence. It may be generated in any manner, including by chemical synthesis.
  • a polypeptide of the invention may be of a size of about 3 or more, 5 or more, 10 or more, 20 or more, 25 or more, 50 or more, 75 or more, 100 or more, 200 or more, 500 or more, 1,000 or more, or 2,000 or more amino acids.
  • Polypeptides may have a defined three-dimensional structure, although they do not necessarily have such structure. Polypeptides with a defined three-dimensional structure are referred to as folded, and polypeptides which do not possess a defined three-dimensional structure, but rather can adopt a large number of different conformations, and are referred to as unfolded.
  • an “isolated” polypeptide or a variant, or derivative thereof is intended a polypeptide that is not in its natural milieu. No particular level of purification is required.
  • an isolated polypeptide can be removed from its native or natural environment.
  • Recombinantly produced polypeptides and proteins expressed in host cells are considered isolated for the purpose of the invention, as are native or recombinant polypeptides which have been separated, fractionated, or partially or substantially purified by any suitable technique.
  • Percent (%) amino acid sequence identity with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
  • % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2.
  • the ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087.
  • the ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code.
  • the ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
  • % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows:
  • polynucleotide refers to an isolated nucleic acid molecule or construct, e.g., messenger RNA (mRNA), virally-derived RNA, or plasmid DNA (pDNA).
  • mRNA messenger RNA
  • pDNA virally-derived RNA
  • a polynucleotide may comprise a conventional phosphodiester bond or a non-conventional bond (e.g., an amide bond, such as found in peptide nucleic acids (PNA).
  • PNA peptide nucleic acids
  • nucleic acid molecule refers to any one or more nucleic acid segments, e.g., DNA or RNA fragments, present in a polynucleotide.
  • isolated nucleic acid molecule or polynucleotide is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment.
  • a recombinant polynucleotide encoding a polypeptide contained in a vector is considered isolated for the purposes of the present invention.
  • Further examples of an isolated polynucleotide include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution.
  • An isolated polynucleotide includes a polynucleotide molecule contained in cells that ordinarily contain the polynucleotide molecule, but the polynucleotide molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
  • Isolated RNA molecules include in vivo or in vitro RNA transcripts of the present invention, as well as positive and negative strand forms, and double-stranded forms. Isolated polynucleotides or nucleic acids according to the present invention further include such molecules produced synthetically.
  • a polynucleotide or a nucleic acid may be or may include a regulatory element such as a promoter, ribosome binding site, or a transcription terminator.
  • nucleic acid or polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence.
  • a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence.
  • These alterations of the reference sequence may occur at the 5’ or 3’ terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.
  • any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs, such as the ones discussed above for polypeptides (e.g., ALIGN-2).
  • expression cassette refers to a polynucleotide generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a target cell.
  • the recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment.
  • the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid sequence to be transcribed and a promoter.
  • the expression cassette of the invention comprises polynucleotide sequences that encode bispecific antigen binding molecules of the invention or fragments thereof.
  • vector or "expression vector” is synonymous with "expression construct” and refers to a DNA molecule that is used to introduce and direct the expression of a specific gene to which it is operably associated in a target cell.
  • the term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced.
  • the expression vector of the present invention comprises an expression cassette. Expression vectors allow transcription of large amounts of stable mRNA. Once the expression vector is inside the target cell, the ribonucleic acid molecule or protein that is encoded by the gene is produced by the cellular transcription and/or translation machinery.
  • the expression vector of the invention comprises an expression cassette that comprises polynucleotide sequences that encode bispecific antigen binding molecules of the invention or fragments thereof.
  • host cell refers to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells.
  • Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.
  • a host cell is any type of cellular system that can be used to generate the bispecific antigen binding molecules of the present invention.
  • Host cells include cultured cells, e.g., mammalian cultured cells, such as CHO cells, BHK cells, NSO cells, SP2/0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, yeast cells, insect cells, and plant cells, to name only a few, but also cells comprised within a transgenic animal, transgenic plant or cultured plant or animal tissue.
  • mammalian cultured cells such as CHO cells, BHK cells, NSO cells, SP2/0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, yeast cells, insect cells, and plant cells, to name only a few, but also cells comprised within a transgenic animal, transgenic plant or cultured plant or animal tissue.
  • an “activating Fc receptor” is an Fc receptor that following engagement by an Fc domain of an antibody elicits signaling events that stimulate the receptor-bearing cell to perform effector functions.
  • Human activating Fc receptors include FcyRIIIa (CD16a), FcyRI (CD64), FcyRIIa (CD32), and FcaRI (CD89).
  • Antibody-dependent cell-mediated cytotoxicity is an immune mechanism leading to the lysis of antibody-coated target cells by immune effector cells.
  • the target cells are cells to which antibodies or derivatives thereof comprising an Fc region specifically bind, generally via the protein part that is N-terminal to the Fc region.
  • reduced ADCC is defined as either a reduction in the number of target cells that are lysed in a given time, at a given concentration of antibody in the medium surrounding the target cells, by the mechanism of ADCC defined above, and/or an increase in the concentration of antibody in the medium surrounding the target cells, required to achieve the lysis of a given number of target cells in a given time, by the mechanism of ADCC.
  • the reduction in ADCC is relative to the ADCC mediated by the same antibody produced by the same type of host cells, using the same standard production, purification, formulation and storage methods (which are known to those skilled in the art), but that has not been engineered.
  • the reduction in ADCC mediated by an antibody comprising in its Fc domain an amino acid substitution that reduces ADCC is relative to the ADCC mediated by the same antibody without this amino acid substitution in the Fc domain.
  • Suitable assays to measure ADCC are well known in the art (see e.g., PCT publication no. WO 2006/082515 or PCT publication no. WO 2012/130831).
  • an “effective amount” of an agent refers to the amount that is necessary to result in a physiological change in the cell or tissue to which it is administered.
  • a “therapeutically effective amount” of an agent refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
  • a therapeutically effective amount of an agent for example eliminates, decreases, delays, minimizes or prevents adverse effects of a disease.
  • mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and nonhuman primates such as monkeys), rabbits, and rodents (e.g., mice and rats). Particularly, the individual or subject is a human.
  • domesticated animals e.g., cows, sheep, cats, dogs, and horses
  • primates e.g., humans and nonhuman primates such as monkeys
  • rabbits e.g., mice and rats
  • rodents e.g., mice and rats
  • composition refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
  • a “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical composition, other than an active ingredient, which is nontoxic to a subject.
  • a pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
  • treatment refers to clinical intervention in an attempt to alter the natural course of a disease in the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.
  • protease-activatable IL-2 polypeptides or immunoconjugates of the invention are used to delay development of a disease or to slow the progression of a disease.
  • package insert is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.
  • an “idiotype-specific polypeptide” as used herein refers to a polypeptide that recognizes the idiotype of an antigen-binding moiety, e.g., an antigen-binding moiety specific for CD3.
  • the idiotype-specific polypeptide is capable of specifically binding to the variable region of the antigen-binding moiety and thereby reducing or preventing specific binding of the antigenbinding moiety to its cognate antigen.
  • the idiotype-specific polypeptide can function as a masking moiety of the molecule.
  • anti-idiotype antibodies or anti-idiotype-binding antibody fragments specific for the idiotype of anti-CD3 binding molecules are disclosed herein.
  • proteolytic enzyme refers to any proteolytic enzyme that cleaves the linker at a recognition site and that is expressed by a target cell. Such proteases might be secreted by the target cell or remain associated with the target cell, e.g., on the target cell surface.
  • proteases include but are not limited to metalloproteinases, e.g., matrix metalloproteinase 1-28 and A Disintegrin And Metalloproteinase (ADAM) 2, 7-12, 15, 17-23, 28-30 and 33, serine proteases, e.g., urokinase-type plasminogen activator and Matriptase, cysteine protease, aspartic proteases, and members of the cathepsin family.
  • metalloproteinases e.g., matrix metalloproteinase 1-28 and A Disintegrin And Metalloproteinase (ADAM) 2, 7-12, 15, 17-23, 28-30 and 33
  • serine proteases e.g., urokinase-type plasminogen activator and Matriptase
  • cysteine protease aspartic proteases
  • members of the cathepsin family members of the cathepsin family.
  • “Protease activatable” as used herein, with respect to the interleukin-2 polypeptides refers to an interleukin-2 polypeptides having reduced or abrogated ability to bind the interleukin-2 receptor due to a masking moiety that reduces or abrogates the interleukin-2 polypeptides’ s ability to bind to the interleukin-2 receptor.
  • a masking moiety that reduces or abrogates the interleukin-2 polypeptides’ s ability to bind to the interleukin-2 receptor.
  • “Reversibly concealing” as used herein refers to the binding of a masking moiety to an interleukin-2 polypeptide such as to prevent the interleukin-2 polypeptide from binding to its receptor. This concealing is reversible in that the masking moiety can be released from the interleukin-2 polypeptide, e.g. by protease cleavage, and thereby freeing the interleukin-2 polypeptide to bind to its receptor.
  • a protease-activatable interleukin-2 (IL-2) polypeptide comprises (i) an IL-2 polypeptide, (ii) a masking moiety and (iii) a linker comprising a first protease cleavage site, wherein the linker has a length of 20 to 45 amino acids, wherein the masking moiety is covalently attached to the IL-2 polypeptide through the linker, wherein the masking moiety is capable of binding to the IL-2 polypeptide thereby reversibly concealing the IL-2 polypeptide, wherein the masking moiety comprises a second protease cleavage site, wherein the masking moiety does not conceal the IL-2 polypeptide upon cleavage at the first and/or the second protease cleavage site.
  • IL-2 interleukin-2
  • the linker has a length of 22 to 43 amino acids. In a preferred embodiment, the linker has a length of 25 to 38 amino acids. In a preferred embodiment, the linker has a length of 25. In another preferred embodiment, the linker has a length of 38 amino acids.
  • the masking moiety is covalently attached to the amino-terminus or carboxy-terminus of the interleukin-2 polypeptide through the linker. In one embodiment, the masking moiety is an IL-2 antagonist. In one embodiment, the masking moiety is an IL-2 antibody or an IL-2 receptor subunit. In one embodiment, the IL-2 antibody comprises a Fab molecule.
  • the masking moiety is an antibody derived from MT204, preferably MT204.
  • the MT204 antibody is disclosed e.g. in Volkland et al., Molecular Immunology 44 (2007) 1743-1753, and PCT-publication WO 2006/128690 AL
  • the masking moiety is a de-immunized MT204- derived binder.
  • the MT204-derived masking moiety comprises a VL domain according to SEQ ID NO: 55 and a VH domain according to SEQ ID NO: 56.
  • the Fab molecule is a single-chain Fab molecule.
  • the second protease cleavage site is located between the variable domain of the heavy chain (VH) and the variable domain of the light chain (VL) of the single-chain Fab molecule.
  • the first protease cleavage site and the second protease cleavage site each comprise at least one protease recognition sequence.
  • the protease recognition sequence of the first protease cleavage site and/or the protease recognition sequence of the second protease cleavage site is either YAARKGGI according to SEQ ID NO:60 and/or PQARK according to SEQ ID NO:61.
  • the protease recognition sequence of the first protease cleavage site is YAARKGGI according to SEQ ID NO:60 or PQARK according to SEQ ID NO:61.
  • the protease recognition sequence of the second protease cleavage site is YAARKGGI according to SEQ ID NO:60 or PQARK according to SEQ ID NO:61.
  • the protease recognition sequence of the first protease cleavage site is YAARKGGI according to SEQ ID NO:60 and the protease recognition sequence of the second protease cleavage site is PQARK according to SEQ ID NO:61.
  • the protease recognition sequence of the first protease cleavage site is PQARK according to SEQ ID NO:61 and the protease recognition sequence of the second protease cleavage site is YAARKGGI according to SEQ ID NO:60.
  • the IL-2 polypeptide is a wild-type IL-2, preferably a human IL-2 according to SEQ ID NO: 62, or a mutant IL-2 polypeptide.
  • the mutant IL-2 polypeptide comprises any amino acid substitution selected from the group T3A, F42A, Y45A, L72G, C125A of human IL-2 according to SEQ ID NO:62.
  • the mutant IL-2 polypeptide comprises the amino acid substitutions F42A, Y45A and L72G of human IL-2 according to SEQ ID NO:62.
  • the mutant IL-2 polypeptide comprises the amino acid substitutions T3A, F42A, Y45A, L72G and C125A of human IL-2 according to SEQ ID NO:62.
  • the protease-activatable IL-2 polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 27. In one specific embodiment, the protease-activatable IL-2 polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 28. In one specific embodiment, the protease- activatable IL-2 polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 29.
  • the protease-activatable IL-2 polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 30. In one specific embodiment, the protease-activatable IL-2 polypeptide comprises an amino acid sequence according to SEQ ID NO: 27. In one specific embodiment, the protease-activatable IL- 2 polypeptide comprises an amino acid sequence according to SEQ ID NO: 28. In one specific embodiment, the protease-activatable IL-2 polypeptide comprises an amino acid sequence o according to SEQ ID NO: 29. In one specific embodiment, the protease-activatable IL-2 polypeptide comprises an amino acid sequence according to SEQ ID NO: 30.
  • the IL-2 polypeptide is further attached to a non-IL-2 moiety.
  • the IL-2 polypeptide shares a carboxy-terminal peptide bond with the masking moiety and an amino-terminal peptide bond with the non-IL-2 moiety.
  • or the IL-2 polypeptide shares an amino-terminal peptide bond with the masking moiety and a carboxy-terminal peptide bond with the non-IL-2 moiety.
  • the non-IL-2 moiety is an antigen binding moiety or an effector cell binding moiety.
  • the invention provides an immunoconjugate comprising a protease- activatable IL-2 polypeptide as described herein and an antigen binding moiety and an effector cell binding moiety. In one embodiment, the invention provides an immunoconjugate comprising a protease-activatable IL-2 polypeptide as described herein and an antigen binding moiety. In one embodiment, the invention provides an immunoconjugate comprising a protease-activatable IL-2 polypeptide as described herein and an effector cell binding moiety.
  • the protease-activatable IL-2 polypeptide shares an amino- or carboxy- terminal peptide bond with the antigen binding moiety or the effector cell binding moiety.
  • the immunoconjugate comprises a first and a second antigen binding moiety or a first and a second effector cell antigen binding moiety or an antigen binding moiety and an effector cell binding moiety.
  • the protease-activatable IL-2 polypeptide shares an amino- or carboxy-terminal peptide bond with said first antigen binding moiety and said second antigen binding moiety shares an amino- or carboxy-terminal peptide bond with either a) said protease-activatable IL-2 polypeptide or b) said first antigen binding moiety;
  • the protease-activatable IL-2 polypeptide shares an amino- or carboxy-terminal peptide bond with said first effector cell binding moiety and said second effector cell binding moiety shares an amino- or carboxy-terminal peptide bond with either a) said protease-activatable IL-2 polypeptide or b) said first effector cell binding moiety;
  • the protease-activatable IL-2 polypeptide shares an amino- or carboxy-terminal peptide bond with the antigen binding moiety and the effector cell binding moiety shares an amino- or carboxy-terminal
  • the antigen binding moiety or the effector cell binding moiety comprised in the protease-activatable IL-2 polypeptide as disclosed herein or the immunoconjugate as disclosed herein is an antibody or an antibody fragment.
  • the antigen binding moiety and/or said effector cell binding moiety is selected from a Fab molecule and a scFv molecule.
  • the antigen binding moiety and/or said effector cell binding moiety is an immunoglobulin molecule, particularly an IgG molecule.
  • the antigen binding moiety is directed to an antigen presented on a tumor cell or in a tumor cell environment and/or wherein said effector cell binding moiety is directed to an effector cell present in a tumor cell environment in order to achieve cis-targeting.
  • the immunoconjugate comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 5, an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 22, and an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 23.
  • the immunoconjugate comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 5, an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 22, and an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 24.
  • the immunoconjugate comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 5, an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 22, and an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 25.
  • the immunoconjugate comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 5, an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 22, and an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 26.
  • the immunoconjugate comprises an amino acid sequence according to SEQ ID NO: 23. In one specific embodiment, the immunoconjugate comprises an amino acid sequence according to SEQ ID NO: 24. In one specific embodiment, the immunoconjugate comprises an amino acid sequence according to SEQ ID NO: 25. In one specific embodiment, the immunoconjugate comprises an amino acid sequence according to SEQ ID NO: 26.
  • the immunoconjugate comprises an amino acid sequence according to SEQ ID NO: 5, an amino acid sequence according to SEQ ID NO: 22, and an amino acid sequence according to SEQ ID NO: 23. In one specific embodiment, the immunoconjugate comprises an amino acid sequence according to SEQ ID NO: 5, an amino acid sequence according to SEQ ID NO: 22, and an amino acid sequence according to SEQ ID NO: 24. In one specific embodiment, the immunoconjugate comprises an amino acid sequence according to SEQ ID NO: 5, an amino acid sequence according to SEQ ID NO: 22, and an amino acid sequence according to SEQ ID NO: 25. In one specific embodiment, the immunoconjugate comprises an amino acid sequence according to SEQ ID NO: 5, an amino acid sequence according to SEQ ID NO: 22, and an amino acid sequence according to SEQ ID NO: 26.
  • the protease-activatable IL-2 polypeptide of the invention comprises at least one masking moiety.
  • the masking moiety masks the IL-2 polypeptide and comprises at least one of the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2, and the light chain CDR3 of a MT204 derived Fab antibody.
  • the masking moiety masks the IL-2 polypeptide and comprises at least one of the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2, and the light chain CDR3 of a MT204 derived Fab antibody with the amino acid sequence of SEQ ID NO: 55 and SEQ ID NO: 56.
  • the masking moiety comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3 as in the VH domain according to SEQ ID NO: 56, and the light chain CDR1, the light chain CDR2, and the light chain CDR3 as in the VL domain according to SEQ ID NO: 55.
  • the masking moiety that masks the IL-2 polypeptide comprises a VL domain according to SEQ ID NO: 55 and a VH domain according to SEQ ID NO: 56, wherein the masking moiety is a single-chain Fab molecule.
  • the protease-activatable IL-2 polypeptide or the immunoconjugate comprises a linker having a protease recognition site comprising a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 63, 64, 65 or 66.
  • the protease recognition site comprises the polypeptide sequence of SEQ ID NO: 63, 64, 65 or 66.
  • Polynucleotides The invention further provides isolated polynucleotides encoding a protease-activatable IL-2 polypeptide or immunoconjugate as described herein or a fragment thereof.
  • polypeptides encoding protease-activatable IL-2 polypeptides or immunoconjugates of the invention may be expressed as a single polynucleotide that encodes the entire protease- activatable IL-2 polypeptides or immunoconjugates or as multiple (e.g., two or more) polynucleotides that are co-expressed.
  • Polypeptides encoded by polynucleotides that are coexpressed may associate through, e.g., disulfide bonds or other means to form a functional protease-activatable IL-2 polypeptides or immunoconjugates.
  • the light chain portion of an antigen binding moiety may be encoded by a separate polynucleotide from the polynucleotide encoding the heavy chain of the immunconjugate, an Fc domain subunit and optionally (part of) another antigen binding moiety.
  • the heavy chain polypeptides When co-expressed, the heavy chain polypeptides will associate with the light chain polypeptides to form the antigen binding moiety.
  • the portion immunconjugate comprising one of the two Fc domain subunits and optionally (part of) one or more antigen binding moieties could be encoded by a separate polynucleotide from the portion of the immunoconjugate comprising the other of the two Fc domain subunits and optionally (part of) an antigen binding moiety. When co-expressed, the Fc domain subunits will associate to form the Fc domain.
  • the isolated polynucleotide encodes the entire immunoconjugate according to the invention as described herein. In other embodiments, the isolated polynucleotide encodes a polypeptides comprised in the immunoconjugate according to the invention as described herein.
  • the present invention is directed to an isolated polynucleotide encoding a protease-activatable IL-2 polypeptide or immunoconjugate of the invention or a fragment thereof.
  • the polynucleotide or nucleic acid is DNA.
  • a polynucleotide of the present invention is RNA, for example, in the form of messenger RNA (mRNA).
  • mRNA messenger RNA
  • RNA of the present invention may be single stranded or double stranded.
  • the IL-2 polypeptide or immunconjugate of the invention may be obtained, for example, by solid-state peptide synthesis (e.g., Merrifield solid phase synthesis) or recombinant production.
  • solid-state peptide synthesis e.g., Merrifield solid phase synthesis
  • one or more polynucleotide encoding the protease-activatable IL-2 polypeptide or immunconjugate, e.g., as described above is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell.
  • Such polynucleotide may be readily isolated and sequenced using conventional procedures.
  • a vector, preferably an expression vector, comprising one or more of the polynucleotides of the invention is provided.
  • the expression vector can be part of a plasmid, virus, or may be a nucleic acid fragment.
  • the expression vector includes an expression cassette into which the polynucleotide encoding the protease-activatable IL-2 polypeptide or immunconjugate (i.e. the coding region) is cloned in operable association with a promoter and/or other transcription or translation control elements.
  • a "coding region" is a portion of nucleic acid which consists of codons translated into amino acids.
  • a "stop codon" (TAG, TGA, or TAA) is not translated into an amino acid, it may be considered to be part of a coding region, if present, but any flanking sequences, for example promoters, ribosome binding sites, transcriptional terminators, introns, 5' and 3' untranslated regions, and the like, are not part of a coding region.
  • Two or more coding regions can be present in a single polynucleotide construct, e.g., on a single vector, or in separate polynucleotide constructs, e.g., on separate (different) vectors.
  • any vector may contain a single coding region, or may comprise two or more coding regions, e.g., a vector of the present invention may encode one or more polypeptides, which are post- or co-translationally separated into the final proteins via proteolytic cleavage.
  • a vector, polynucleotide, or nucleic acid of the invention may encode heterologous coding regions, either fused or unfused to a polynucleotide encoding the protease-activatable IL- 2 polypeptide or immunoconjugate of the invention, or variant or derivative thereof.
  • Heterologous coding regions include without limitation specialized elements or motifs, such as a secretory signal peptide or a heterologous functional domain.
  • An operable association is when a coding region for a gene product, e.g., a polypeptide, is associated with one or more regulatory sequences in such a way as to place expression of the gene product under the influence or control of the regulatory sequence(s).
  • Two DNA fragments (such as a polypeptide coding region and a promoter associated therewith) are "operably associated” if induction of promoter function results in the transcription of mRNA encoding the desired gene product and if the nature of the linkage between the two DNA fragments does not interfere with the ability of the expression regulatory sequences to direct the expression of the gene product or interfere with the ability of the DNA template to be transcribed.
  • a promoter region would be operably associated with a nucleic acid encoding a polypeptide if the promoter was capable of effecting transcription of that nucleic acid.
  • the promoter may be a cell-specific promoter that directs substantial transcription of the DNA only in predetermined cells.
  • Other transcription control elements besides a promoter, for example enhancers, operators, repressors, and transcription termination signals, can be operably associated with the polynucleotide to direct cell-specific transcription. Suitable promoters and other transcription control regions are disclosed herein. A variety of transcription control regions are known to those skilled in the art.
  • transcription control regions which function in vertebrate cells, such as, but not limited to, promoter and enhancer segments from cytomegaloviruses (e.g., the immediate early promoter, in conjunction with intron-A), simian virus 40 (e.g., the early promoter), and retroviruses (such as, e.g., Rous sarcoma virus).
  • transcription control regions include those derived from vertebrate genes such as actin, heat shock protein, bovine growth hormone and rabbit a-globin, as well as other sequences capable of controlling gene expression in eukaryotic cells.
  • tissue-specific promoters and enhancers as well as inducible promoters (e.g., promoters inducible tetracyclins).
  • inducible promoters e.g., promoters inducible tetracyclins
  • translation control elements include, but are not limited to ribosome binding sites, translation initiation and termination codons, and elements derived from viral systems (particularly an internal ribosome entry site, or IRES, also referred to as a CITE sequence).
  • the expression cassette may also include other features such as an origin of replication, and/or chromosome integration elements such as retroviral long terminal repeats (LTRs), or adeno-associated viral (AAV) inverted terminal repeats (ITRs).
  • LTRs retroviral long terminal repeats
  • AAV adeno-associated viral inverted terminal repeats
  • Polynucleotide and nucleic acid coding regions of the present invention may be associated with additional coding regions which encode secretory or signal peptides, which direct the secretion of a polypeptide encoded by a polynucleotide of the present invention.
  • additional coding regions which encode secretory or signal peptides, which direct the secretion of a polypeptide encoded by a polynucleotide of the present invention.
  • DNA encoding a signal sequence may be placed upstream of the nucleic acid encoding a protease-activatable IL-2 polypeptide or immunconjugate of the invention or a fragment thereof.
  • proteins secreted by mammalian cells have a signal peptide or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated.
  • polypeptides secreted by vertebrate cells generally have a signal peptide fused to the N-terminus of the polypeptide, which is cleaved from the translated polypeptide to produce a secreted or "mature" form of the polypeptide.
  • the native signal peptide e.g., an immunoglobulin heavy chain or light chain signal peptide is used, or a functional derivative of that sequence that retains the ability to direct the secretion of the polypeptide that is operably associated with it.
  • a heterologous mammalian signal peptide, or a functional derivative thereof may be used.
  • the wild-type leader sequence may be substituted with the leader sequence of human tissue plasminogen activator (TPA) or mouse P- glucuronidase.
  • DNA encoding a short protein sequence that could be used to facilitate later purification (e.g., a histidine tag) or assist in labeling the protease-activatable IL-2 polypeptide or immunconjugate may be included within or at the ends of the protease-activatable IL-2 polypeptide or immunconjugate encoding polynucleotide.
  • a host cell comprising one or more polynucleotides of the invention.
  • a host cell comprising one or more vectors of the invention.
  • the polynucleotides and vectors may incorporate any of the features, singly or in combination, described herein in relation to polynucleotides and vectors, respectively.
  • a host cell comprises (e.g., has been transformed or transfected with) a vector comprising a polynucleotide that encodes (part of) a protease-activatable IL-2 polypeptide or immunconjugate of the invention.
  • the term "host cell” refers to any kind of cellular system which can be engineered to generate the protease-activatable IL-2 polypeptide or immunconjugate of the invention or fragments thereof.
  • Host cells suitable for replicating and for supporting expression of protease-activatable IL-2 polypeptides or immunconjugates are well known in the art. Such cells may be transfected or transduced as appropriate with the particular expression vector and large quantities of vector containing cells can be grown for seeding large scale fermenters to obtain sufficient quantities of the IL-2 polypeptide or immunconjugate for clinical applications.
  • Suitable host cells include prokaryotic microorganisms, such as E.
  • polypeptides may be produced in bacteria in particular when glycosylation is not needed. After expression, the polypeptide may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.
  • eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for polypeptide-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized”, resulting in the production of a polypeptide with a partially or fully human glycosylation pattern.
  • Suitable host cells for the expression of (glycosylated) polypeptides are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells. Plant cell cultures can also be utilized as hosts. See e.g., US Patent Nos.
  • Vertebrate cells may also be used as hosts.
  • Vertebrate cells may also be used as hosts.
  • mammalian cell lines that are adapted to grow in suspension may be useful.
  • TM4 cells as described, e.g., in Mather, Biol Reprod 23, 243-251 (1980)
  • monkey kidney cells CV1
  • African green monkey kidney cells VERO-76
  • human cervical carcinoma cells HELA
  • canine kidney cells MDCK
  • buffalo rat liver cells BBL 3 A
  • human lung cells W138
  • human liver cells Hep G2
  • mouse mammary tumor cells MMT 060562
  • TRI cells as described, e.g., in Mather et al., Annals N.Y.
  • MRC 5 cells MRC 5 cells
  • FS4 cells Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including dhfr CHO cells (Urlaub et al., Proc Natl Acad Sci USA 77, 4216 (1980)); and myeloma cell lines such as YO, NS0, P3X63 and Sp2/0.
  • CHO Chinese hamster ovary
  • dhfr CHO cells Urlaub et al., Proc Natl Acad Sci USA 77, 4216 (1980)
  • myeloma cell lines such as YO, NS0, P3X63 and Sp2/0.
  • Host cells include cultured cells, e.g., mammalian cultured cells, yeast cells, insect cells, bacterial cells and plant cells, to name only a few, but also cells comprised within a transgenic animal, transgenic plant or cultured plant or animal tissue.
  • the host cell is a eukaryotic cell, preferably a mammalian cell, such as a Chinese Hamster Ovary (CHO) cell, a human embryonic kidney (HEK) cell or a lymphoid cell (e.g., Y0, NS0, Sp20 cell).
  • CHO Chinese Hamster Ovary
  • HEK human embryonic kidney
  • a lymphoid cell e.g., Y0, NS0, Sp20 cell.
  • Cells expressing a polypeptide comprising either the heavy or the light chain of an antigen binding domain such as an antibody may be engineered so as to also express the other of the antibody chains such that the expressed product is an antibody that has both a heavy and a light chain.
  • a method of producing a protease- IL-2 polypeptide or immunconjugate according to the invention comprises culturing a host cell comprising a polynucleotide encoding the protease-activatable IL-2 polypeptide or immunconjugate, as provided herein, under conditions suitable for expression of the protease- activatable IL-2 polypeptide or immunconjugate, and recovering the protease-activatable IL-2 polypeptide or immunconjugate from the host cell (or host cell culture medium).
  • protease-activatable IL-2 polypeptide or immunconjugate are genetically fused to each other.
  • Protease-activatable IL-2 polypeptides or immunconjugates can be designed such that its components are fused directly to each other or indirectly through a linker sequence.
  • the composition and length of the linker may be determined in accordance with methods well known in the art and may be tested for efficacy. Examples of linker sequences between different components of protease-activatable IL-2 polypeptides or immunconjugates are found in the sequences provided herein. Additional sequences may also be included to incorporate a cleavage site to separate the individual components of the fusion if desired, for example an endopeptidase recognition sequence.
  • the one or more antigen binding moieties of the immunoconjugates comprise at least an antibody variable region capable of binding an antigenic determinant.
  • Variable regions can form part of and be derived from naturally or non-naturally occurring antibodies and fragments thereof.
  • Methods to produce polyclonal antibodies and monoclonal antibodies are well known in the art (see e.g., Harlow and Lane, "Antibodies, a laboratory manual", Cold Spring Harbor Laboratory, 1988).
  • Non-naturally occurring antibodies can be constructed using solid phase-peptide synthesis, can be produced recombinantly (e.g., as described in U.S. patent No. 4,186,567) or can be obtained, for example, by screening combinatorial libraries comprising variable heavy chains and variable light chains (see e.g., U.S. Patent. No. 5,969,108 to McCafferty).
  • any animal species of antibody, antibody fragment, antigen binding domain or variable region can be used in the immunoconjugates of the invention.
  • Non-limiting antibodies, antibody fragments, antigen binding domains or variable regions useful in the present invention can be of murine, primate, or human origin. If the protease-activatable IL-2 polypeptide or immunconjugate is intended for human use, a chimeric form of antibody may be used wherein the constant regions of the antibody are from a human.
  • a “humanized” or fully human form of the antibody can also be prepared in accordance with methods well known in the art (see e. g. U.S. Patent No. 5,565,332 to Winter).
  • Humanization may be achieved by various methods including, but not limited to (a) grafting the non-human (e.g., donor antibody) CDRs onto human (e.g., recipient antibody) framework and constant regions with or without retention of critical framework residues (e.g., those that are important for retaining good antigen binding affinity or antibody functions), (b) grafting only the non-human specificity-determining regions (SDRs or a-CDRs; the residues critical for the antibody-antigen interaction) onto human framework and constant regions, or (c) transplanting the entire non-human variable domains, but "cloaking" them with a human-like section by replacement of surface residues.
  • a grafting the non-human (e.g., donor antibody) CDRs onto human (e.g., recipient antibody) framework and constant regions with or without retention of critical framework residues (e.g., those that are important for retaining good antigen binding affinity or antibody functions)
  • SDRs or a-CDRs the residues critical for the antibody-
  • Human antibodies and human variable regions can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk and van de Winkel, Curr Opin Pharmacol 5, 368-74 (2001) and Lonberg, Curr Opin Immunol 20, 450-459 (2008). Human variable regions can form part of and be derived from human monoclonal antibodies made by the hybridoma method (see e.g., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).
  • Human antibodies and human variable regions may also be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge (see e.g., Lonberg, Nat Biotech 23, 1117-1125 (2005). Human antibodies and human variable regions may also be generated by isolating Fv clone variable region sequences selected from human-derived phage display libraries (see e.g., Hoogenboom et al.
  • Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments.
  • the antigen binding moieties useful in the present invention are engineered to have enhanced binding affinity according to, for example, the methods disclosed in U.S. Pat. Appl. Publ. No. 2004/0132066, the entire contents of which are hereby incorporated by reference.
  • the ability of the immunoconjugate of the invention to bind to a specific antigenic determinant can be measured either through an enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to one of skill in the art, e.g., surface plasmon resonance technique (analyzed on a BIACORE T100 system) (Liljeblad, et al., Glyco J 17, 323-329 (2000)), and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)).
  • ELISA enzyme-linked immunosorbent assay
  • Competition assays may be used to identify an antibody, antibody fragment, antigen binding domain or variable domain that competes with a reference antibody for binding to a particular antigen.
  • such a competing antibody binds to the same epitope (e.g., a linear or a conformational epitope) that is bound by the reference antibody.
  • epitope e.g., a linear or a conformational epitope
  • Detailed exemplary methods for mapping an epitope to which an antibody binds are provided in Morris (1996) “Epitope Mapping Protocols,” in Methods in Molecular Biology vol. 66 (Humana Press, Totowa, NJ).
  • Protease-activatable IL-2 polypeptides or immunoconjugate s prepared as described herein may be purified by art-known techniques such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, and the like.
  • an antibody, ligand, receptor or antigen can be used to which the protease-activatable IL-2 polypeptide or immunconjugate binds.
  • a matrix with protein A or protein G may be used.
  • Sequential Protein A or G affinity chromatography and size exclusion chromatography can be used to isolate a protease-activatable IL-2 polypeptide or immunconjugate.
  • the purity of the protease- activatable IL-2 polypeptide or immunconjugate can be determined by any of a variety of well- known analytical methods including gel electrophoresis, high pressure liquid chromatography, and the like.
  • Protease-activatable IL-2 polypeptides or immunconjugates provided herein may be identified, screened for, or characterized for their physical/chemical properties and/or biological activities by various assays known in the art.
  • the affinity of the immunoconjugate for an Fc receptor or a target antigen can be determined in accordance with the methods set forth in the Examples by surface plasmon resonance (SPR), using standard instrumentation such as a BIAcore instrument (GE Healthcare), and receptors or target proteins such as may be obtained by recombinant expression.
  • SPR surface plasmon resonance
  • BIAcore instrument GE Healthcare
  • receptors or target proteins such as may be obtained by recombinant expression.
  • binding of protease-activatable IL-2 polypeptides or immunconjugates for different receptors or target antigens may be evaluated using cell lines expressing the particular receptor or target antigen, for example by flow cytometry (FACS).
  • FACS flow cytometry
  • KD is measured by surface plasmon resonance using a BIACORE® T100 machine (GE Healthcare) at 25 °C.
  • CM5 chips To analyze the interaction between the Fc-portion and Fc receptors, His-tagged recombinant Fc- receptor is captured by an anti-Penta His antibody (Qiagen) immobilized on CM5 chips and the bispecific constructs are used as analytes. Briefly, carboxymethylated dextran biosensor chips (CM5, GE Healthcare) are activated with N-ethyl-N’-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier’s instructions.
  • CM5 carboxymethylated dextran biosensor chips
  • EDC N-ethyl-N’-(3-dimethylaminopropyl)-carbodiimide hydrochloride
  • NHS N-hydroxysuccinimide
  • Anti Penta-His antibody is diluted with 10 mM sodium acetate, pH 5.0, to 40 pg/ml before injection at a flow rate of 5 pl/min to achieve approximately 6500 response units (RU) of coupled protein. Following the injection of the ligand, 1 M ethanolamine is injected to block unreacted groups. Subsequently the Fc-receptor is captured for 60 s at 4 or 10 nM.
  • HBS-EP GE Healthcare, 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05 % Surfactant P20, pH 7.4
  • HBS-EP GE Healthcare, 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05 % Surfactant P20, pH 7.4
  • bispecific constructs are captured by an antihuman Fab specific antibody (GE Healthcare) that is immobilized on an activated CM5-sensor chip surface as described for the anti Penta-His antibody.
  • the final amount of coupled protein is approximately 12000 RU.
  • the bispecific constructs are captured for 90 s at 300 nM.
  • the target antigens are passed through the flow cells for 180 s at a concentration range from 250 to 1000 nM with a flowrate of 30 pl/min.
  • the dissociation is monitored for 180 s. Bulk refractive index differences are corrected for by subtracting the response obtained on reference flow cell.
  • the steady state response was used to derive the dissociation constant KD by non-linear curve fitting of the Langmuir binding isotherm.
  • Association rates (k on ) and dissociation rates (k 0 ff) are calculated using a simple one-to-one Langmuir binding model (BIACORE® T100 Evaluation Software version 1.1.1) by simultaneously fitting the association and dissociation sensorgrams.
  • the equilibrium dissociation constant (KD) is calculated as the ratio koir/kon. See, e.g., Chen et al., J Mol Biol 293, 865-881 (1999).
  • Biological activity of the protease-activatable IL-2 polypeptides or immunconjugates of the invention can be measured by various assays as described in the Examples.
  • Biological activities may for example include the induction of proliferation of T cells, the induction of signaling in T cells, the induction of expression of activation markers in T cells, the induction of cytokine secretion by T cells, the induction of lysis of target cells such as tumor cells, and the induction of tumor regression and/or the improvement of survival.
  • compositions Compositions, Formulations, and Routes of Administration
  • the invention provides pharmaceutical compositions comprising any of the protease-activatable IL-2 polypeptides or immunconjugates provided herein, e.g., for use in any of the below therapeutic methods.
  • a pharmaceutical composition comprises any of the protease-activatable IL-2 polypeptides or immunconjugates provided herein and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition comprises any of the protease-activatable IL-2 polypeptides or immunconjugates provided herein and at least one additional therapeutic agent, e.g., as described below.
  • a method of producing a protease-activatable IL-2 polypeptide or immunconjugate of the invention in a form suitable for administration in vivo comprising (a) obtaining a protease-activatable IL-2 polypeptide or immunconjugate according to the invention, and (b) formulating the protease-activatable IL-2 polypeptide or immunconjugate with at least one pharmaceutically acceptable carrier, whereby a preparation of protease-activatable IL-2 polypeptide or immunconjugate is formulated for administration in vivo.
  • compositions of the present invention comprise a therapeutically effective amount of one or more protease-activatable IL-2 polypeptide or immunconjugate dissolved or dispersed in a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable refers to molecular entities and compositions that are generally non-toxic to recipients at the dosages and concentrations employed, i.e. do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate.
  • compositions that contain at least one protease-activatable IL-2 polypeptide or immunconjugate and optionally an additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated herein by reference. Moreover, for animal (e.g., human) administration, it will be understood that preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biological Standards or corresponding authorities in other countries. Preferred compositions are lyophilized formulations or aqueous solutions.
  • pharmaceutically acceptable carrier includes any and all solvents, buffers, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, antioxidants, proteins, drugs, drug stabilizers, polymers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated herein by reference). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
  • composition may comprise different types of carriers depending on whether it is to be administered in solid, liquid or aerosol form, and whether it need to be sterile for such routes of administration as injection.
  • Protease-activatable IL-2 polypeptides or immunconjugates of the present invention can be administered intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrasplenically, intrarenally, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctivally, intravesicularlly, mucosally, intrapericardially, intraumbilically, intraocularally, orally, topically, locally, by inhalation (e.g., aerosol inhalation), injection, infusion, continuous infusion, localized perfusion bathing target cells directly, via a
  • Parenteral administration in particular intravenous injection, is most commonly used for administering polypeptide molecules such as the protease-activatable IL-2 polypeptide or immunconjugate of the invention.
  • compositions include those designed for administration by injection, e.g., subcutaneous, intradermal, intralesional, intravenous, intraarterial intramuscular, intrathecal or intraperitoneal injection.
  • the protease-activatable IL-2 polypeptides or immunconjugates of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer.
  • the solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the protease-activatable IL-2 polypeptides or immunconjugates may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • a suitable vehicle e.g., sterile pyrogen-free water
  • Sterile injectable solutions are prepared by incorporating the protease-activatable IL- 2 polypeptides or immunconjugates of the invention in the required amount in the appropriate solvent with various of the other ingredients enumerated below, as required.
  • Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and/or the other ingredients.
  • the preferred methods of preparation are vacuum-drying or freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile- filtered liquid medium thereof.
  • the liquid medium should be suitably buffered if necessary and the liquid diluent first rendered isotonic prior to injection with sufficient saline or glucose.
  • the composition must be stable under the conditions of manufacture and storage, and preserved against the contaminating action of microorganisms, such as bacteria and fungi. It will be appreciated that endotoxin contamination should be kept minimally at a safe level, for example, less that 0.5 ng/mg protein.
  • Suitable pharmaceutically acceptable carriers include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides
  • Aqueous injection suspensions may contain compounds which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, dextran, or the like.
  • the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • suspensions of the active compounds may be prepared as appropriate oily injection suspensions.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl cleats or triglycerides, or liposomes.
  • Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatinmicrocapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules
  • Sustained-release preparations may be prepared.
  • sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, e.g., films, or microcapsules.
  • prolonged absorption of an injectable composition can be brought about by the use in the compositions of agents delaying absorption, such as, for example, aluminum monostearate, gelatin or combinations thereof.
  • the protease-activatable IL-2 polypeptides or immunoconjugates may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the protease-activatable IL-2 polypeptides or immunoconjugates may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • compositions comprising the protease-activatable IL-2 polypeptides or immunoconjugates of the invention may be manufactured by means of conventional mixing, dissolving, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the proteins into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • the protease-activatable IL-2 polypeptides or immunoconjugates may be formulated into a composition in a free acid or base, neutral or salt form.
  • Pharmaceutically acceptable salts are salts that substantially retain the biological activity of the free acid or base. These include the acid addition salts, e.g., those formed with the free amino groups of a proteinaceous composition, or which are formed with inorganic acids such as for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric or mandelic acid.
  • Salts formed with the free carboxyl groups can also be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine. Pharmaceutical salts tend to be more soluble in aqueous and other protic solvents than are the corresponding free base forms.
  • protease-activatable IL-2 polypeptides or immunoconjugates may be used in therapeutic methods.
  • Protease-activatable IL-2 polypeptides or immunoconjugates of the invention can be used as immunotherapeutic agents, for example in the treatment of cancers.
  • protease-activatable IL-2 polypeptides or immunoconjugates of the invention would be formulated, dosed, and administered in a fashion consistent with good medical practice.
  • Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
  • protease-activatable IL-2 polypeptides or immunoconjugates of the invention for use as a medicament are provided.
  • protease-activatable IL-2 polypeptides or immunoconjugates of the invention for use in treating a disease are provided.
  • protease-activatable IL-2 polypeptides or immunoconjugates of the invention for use in a method of treatment are provided.
  • the invention provides a protease-activatable IL-2 polypeptide or immunoconjugate as described herein for use in the treatment of a disease in an individual in need thereof.
  • the invention provides a protease-activatable IL-2 polypeptide or immunoconjugate for use in a method of treating an individual having a disease comprising administering to the individual a therapeutically effective amount of the protease-activatable IL-2 polypeptide or immunoconjugate.
  • the disease to be treated is a proliferative disorder.
  • the disease is cancer.
  • the method further comprises administering to the individual a therapeutically effective amount of at least one additional therapeutic agent, e.g., an anti-cancer agent if the disease to be treated is cancer.
  • the invention provides a protease-activatable IL-2 polypeptide or immunoconjugate as described herein for use in inducing lysis of a target cell, particularly a tumor cell.
  • the invention provides a protease-activatable IL-2 polypeptide or immunoconjugate for use in a method of inducing lysis of a target cell, particularly a tumor cell, in an individual comprising administering to the individual an effective amount of the protease-activatable IL-2 polypeptide or immunoconjugate to induce lysis of a target cell.
  • An “individual” according to any of the above embodiments is a mammal, preferably a human.
  • the invention provides for the use of a protease-activatable IL-2 polypeptide or immunoconjugate of the invention in the manufacture or preparation of a medicament.
  • the medicament is for the treatment of a disease in an individual in need thereof.
  • the medicament is for use in a method of treating a disease comprising administering to an individual having the disease a therapeutically effective amount of the medicament.
  • the disease to be treated is a proliferative disorder.
  • the disease is cancer.
  • the method further comprises administering to the individual a therapeutically effective amount of at least one additional therapeutic agent, e.g., an anti-cancer agent if the disease to be treated is cancer.
  • the medicament is for inducing lysis of a target cell, particularly a tumor cell.
  • the medicament is for use in a method of inducing lysis of a target cell, particularly a tumor cell, in an individual comprising administering to the individual an effective amount of the medicament to induce lysis of a target cell.
  • An “individual” according to any of the above embodiments may be a mammal, preferably a human.
  • the invention provides a method for treating a disease.
  • the method comprises administering to an individual having such disease a therapeutically effective amount of a protease-activatable IL-2 polypeptide or immunoconjugate of the invention.
  • a composition is administered to said invididual, comprising the protease-activatable IL-2 polypeptide or immunoconjugate of the invention in a pharmaceutically acceptable form.
  • the disease to be treated is a proliferative disorder.
  • the disease is cancer.
  • the method further comprises administering to the individual a therapeutically effective amount of at least one additional therapeutic agent, e.g., an anti-cancer agent if the disease to be treated is cancer.
  • An “individual” according to any of the above embodiments may be a mammal, preferably a human.
  • the invention provides a method for inducing lysis of a target cell, particularly a tumor cell.
  • the disease to be treated is a proliferative disorder, particularly cancer.
  • cancers include bladder cancer, brain cancer, head and neck cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, esophageal cancer, colon cancer, colorectal cancer, rectal cancer, gastric cancer, prostate cancer, blood cancer, skin cancer, squamous cell carcinoma, bone cancer, and kidney cancer.
  • neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous system (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic region, and urogenital system. Also included are pre-cancerous conditions or lesions and cancer metastases.
  • the cancer is chosen from the group consisting of renal cell cancer, skin cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, head and neck cancer.
  • a skilled artisan readily recognizes that in many cases the protease-activatable IL-2 polypeptide or immunoconjugate may not provide a cure but may only provide partial benefit. In some embodiments, a physiological change having some benefit is also considered therapeutically beneficial. Thus, in some embodiments, an amount of protease-activatable IL-2 polypeptide or immunoconjugate that provides a physiological change is considered an "effective amount" or a "therapeutically effective amount".
  • the subject, patient, or individual in need of treatment is typically a mammal, more specifically a human.
  • an effective amount of a protease-activatable IL-2 polypeptide or immunoconjugate of the invention is administered to a cell. In other embodiments, a therapeutically effective amount of a protease-activatable IL-2 polypeptide or immunoconjugate of the invention is administered to an individual for the treatment of disease.
  • a protease-activatable IL-2 polypeptide or immunoconjugate of the invention when used alone or in combination with one or more other additional therapeutic agents, will depend on the type of disease to be treated, the route of administration, the body weight of the patient, the type of IL-2 polypeptide or immunoconjugate, the severity and course of the disease, whether the IL-2 polypeptide or immunoconjugate is administered for preventive or therapeutic purposes, previous or concurrent therapeutic interventions, the patient's clinical history and response to the protease-activatable IL-2 polypeptide or immunoconjugate and the discretion of the attending physician.
  • the practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.
  • Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.
  • a therapeutically effective dose of the protease-activatable IL-2 polypeptides or immunoconjugates described herein will generally provide therapeutic benefit without causing substantial toxicity.
  • Toxicity and therapeutic efficacy of a protease-activatable IL-2 polypeptide or immunoconjugate can be determined by standard pharmaceutical procedures in cell culture or experimental animals. Cell culture assays and animal studies can be used to determine the LDso (the dose lethal to 50% of a population) and the EDso (the dose therapeutically effective in 50% of a population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio LD50/ED50.
  • protease-activatable IL-2 polypeptides or immunoconjugates that exhibit large therapeutic indices are preferred.
  • the protease-activatable IL-2 polypeptide or immunoconjugate according to the present invention exhibits a high therapeutic index.
  • the data obtained from cell culture assays and animal studies can be used in formulating a range of dosages suitable for use in humans.
  • the dosage lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
  • the dosage may vary within this range depending upon a variety of factors, e.g., the dosage form employed, the route of administration utilized, the condition of the subject, and the like.
  • the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition (see, e.g., Fingl et al., 1975, in: The Pharmacological Basis of Therapeutics, Ch. 1, p. 1, incorporated herein by reference in its entirety).
  • the attending physician for patients treated with protease-activatable IL-2 polypeptides or immunoconjugates of the invention would know how and when to terminate, interrupt, or adjust administration due to toxicity, organ dysfunction, and the like. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity).
  • the magnitude of an administered dose in the management of the disorder of interest will vary with the severity of the condition to be treated, with the route of administration, and the like.
  • the severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods.
  • the dose and perhaps dose frequency will also vary according to the age, body weight, and response of the individual patient.
  • protease-activatable IL-2 polypeptides or immunoconjugates of the invention may be administered in combination with one or more other agents in therapy.
  • a protease- activatable IL-2 polypeptide or immunoconjugate of the invention may be co-administered with at least one additional therapeutic agent.
  • therapeutic agent encompasses any agent administered to treat a symptom or disease in an individual in need of such treatment.
  • additional therapeutic agent may comprise any active ingredients suitable for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
  • an additional therapeutic agent is an immunomodulatory agent, a cytostatic agent, an inhibitor of cell adhesion, a cytotoxic agent, an activator of cell apoptosis, or an agent that increases the sensitivity of cells to apoptotic inducers.
  • the additional therapeutic agent is an anti-cancer agent, for example a microtubule disruptor, an antimetabolite, a topoisomerase inhibitor, a DNA intercalator, an alkylating agent, a hormonal therapy, a kinase inhibitor, a receptor antagonist, an activator of tumor cell apoptosis, or an antiangiogenic agent.
  • Such other agents are suitably present in combination in amounts that are effective for the purpose intended.
  • the effective amount of such other agents depends on the amount of protease- activatable IL-2 polypeptide or immunoconjugate used, the type of disorder or treatment, and other factors discussed above.
  • the protease-activatable IL-2 polypeptide or immunoconjugate are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.
  • combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate compositions), and separate administration, in which case, administration of the protease-activatable IL-2 polypeptide or immunoconjugate of the invention can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent and/or adjuvant.
  • Protease-activatable IL-2 polypeptides or immunoconjugates of the invention can also be used in combination with radiation therapy.
  • an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above comprises a container and a label or package insert on or associated with the container.
  • Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc.
  • the containers may be formed from a variety of materials such as glass or plastic.
  • the container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • At least one active agent in the composition is a protease- activatable IL-2 polypeptide or immunoconjugate of the invention.
  • the label or package insert indicates that the composition is used for treating the condition of choice.
  • the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises a protease-activatable IL-2 polypeptide or immunoconjugate of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
  • the article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition.
  • the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
  • the disclosure provides for a de-immunized PD-1 binder comprising a heavy chain variable region (VH) comprising a heavy chain complementary determining region (HCDR) 1 of SEQ ID NO: 71, a HCDR 2 of SEQ ID NO: 72, and a HCDR 3 of SEQ ID NO: 73, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 68, a LCDR 2 of SEQ ID NO: 69 and a LCDR 3 of SEQ ID NO: 70.
  • VH heavy chain variable region
  • HCDR heavy chain complementary determining region
  • VL light chain variable region
  • the disclosure provides for a de-immunized PD1 binder comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 53 and an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 54.
  • the deimmunized PD-1 binder comprises an amino acid sequence according to SEQ ID NO: 53 and an amino acid sequence according to SEQ ID NO: 54.
  • the disclosure provides for the use of the de-immunized PD-1 binder as disclosed herein, wherein the de-immunized PD-1 binder is present in a therapeutic agent.
  • the therapeutic agent is an isolated polypeptide. More preferably, the therapeutic agent is a cancer treatment.
  • a de-immunized MT204-derived binder comprising a heavy chain variable region (VH) comprising a heavy chain complementary determining region (HCDR) 1 of SEQ ID NO: 77, a HCDR 2 of SEQ ID NO: 78, and a HCDR 3 of SEQ ID NO: 79, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 74, a LCDR 2 of SEQ ID NO: 75 and a LCDR 3 of SEQ ID NO: 76.
  • VH heavy chain variable region
  • HCDR heavy chain complementary determining region
  • LCDR light chain complementarity determining region
  • the disclosure provides for a de-immunized MT204- derived binder comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 55 and an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 56.
  • the de-immunized MT204-derived binder comprises an amino acid sequence according to SEQ ID NO: 55 and an amino acid sequence according to SEQ ID NO: 56.
  • the de-immunized MT204-derived binder is a single-chain Fab.
  • the de-immunized MT204-derived binder is a single-chain Fv.
  • the disclosure provides for the use of the de-immunized MT204-derived binder as disclosed herein, wherein the de-immunized MT204-derrived binder is present in a therapeutic agent.
  • the therapeutic agent is an isolated polypeptide. More preferably, the therapeutic agent is a cancer treatment.
  • the PD1 binder (P1AA0927, SEQ ID NOs 51 and 52) was aligned to the human germline sequence IGHV3-23-01 (Acc No: M99660) for the heavy chain and IGKV4-1-01 (Acc No: Z00023) for the light chain, respectively.
  • IGHV3-23-01 Acc No: M99660
  • IGKV4-1-01 Acc No: Z00023
  • protein sequences with a commercial software for the prediction of MHC class 2 binding peptides (Software: ISPRI; Provider: Epivax).
  • sequence stretches with predicted MHC class 2 binding should be addressed, either by increasing the germline content, or by introducing mutations that reduce the MHC binding score. While maintaining affinity and stability of the antibody.
  • sequence around the Framework 2 and CDR2 of the light chain showed three overlapping peptides with predicted MHC binding. Since germlining would reduce binding properties, we manually picked mutations that reduce the predicted binding score, and then we validated experimentally the maintenance of the desired biochemical properties as disclosed below.
  • the de-immunized PD1 binder used in the examples below comprises the VH sequence of SEQ ID NO:54 and the VL sequence of SEQ ID NO: 53.
  • the IL2 binder MT204 was processed in a similar way.
  • the light chain was compared either to the human germline IGKV1-16-01, or to the trastuzumab VL (CAS number 180288-69-1) sequence, which is considered to be of low immunogenicity.
  • the sequence IGHV3-23-01 Acc No: M99660
  • Optimized sequences then have a higher degree of human germline content.
  • variant MT204_VLla would have a higher homology to the trastuzumab framework (on Kabat position 54).
  • the deimmunized MT204 used in the examples below comprises the VH sequence of SEQ ID NO:56 and the VL sequence of SEQ ID NO: 55.
  • the de-immunized sequences of the anti-IL2v mask (P1AH2050 - P1AH2052) and of the anti- PDl binder (P1AH4157 - P1AH4161, P1AI0356 - P1AI0360, and P1AI1648 - P1AI1652) were cloned as human IgG PG LALA for initial characterization ((Fig.lA-lD).
  • the corresponding cDNAs were gene synthesized and cloned into evitria’s vector system using conventional (non- PCR based) cloning techniques. Plasmid DNA was prepared under low-endotoxin conditions based on anion exchange chromatography. DNA concentration was determined by measuring the absorption at a wavelength of 260 nm. Correctness of the sequences was verified with Sanger sequencing with two sequencing reactions per plasmid.
  • Suspension-adapted CHO KI cells (originally received from ATCC and adapted to serum-free growth in suspension culture at evitria) were used for production.
  • the seed was grown in eviGrow medium, a chemically defined, animal-component free, serum-free medium.
  • Cells were transfected with eviFect, evitria’s custom-made, proprietary transfection reagent, and cells were grown after transfection in eviMake2, an animal-component free, serum-free medium.
  • Supernatant was harvested by centrifugation and subsequent filtration (0.2 pm filter).
  • the IgGs were purified using MabSelectTM SuReTM with Dulbecco's PBS (Lonza BE17-512Q) as wash buffer, 0.1 M Glycine pH 3.5 as elution buffer and 1 M Tris HC1 as neutralization buffer (pH 9). Subsequent size exclusion chromatography was performed on a HiLoad Superdex 200 pg column using the final buffer as running buffer. Dialysis (if needed) was performed using Pierce Slide-A-LyzerTM G2 Dialysis Cassettes with a 2K molecular weight cut off. Antibody concentration (if needed) was performed using Amicon® Ultra Centrifugal Filters with a 30 kDa molecular weight cut off.
  • the concentration was determined by measuring absorption at a wavelength of 280 nm. The extinction coefficient was calculated using a proprietary algorithm at evitria. Purity was determined by analytical size exclusion chromatography with an Agilent AdvanceBio SEC column (300A 2.7 um 7.8 x 300 mm) and DPBS as running buffer at 0.8 ml/min. Endotoxin content was measured with the Charles River Endosafe PTS system.
  • de-immunized anti-IL2v mask sequence derived from P1AH2051, i.e. hu IgGl GL MT204_VLla - combo VH2 & VH6 PG LALA
  • de-immunized anti-PDl binder sequence derived from P1AH4157, i.e. PD1-376 VL2 VH4
  • P1AH4157 i.e. PD1-376 VL2 VH4
  • Masked IL2v comprising the IL2v cytokine and the C-terminally fused scFv mask, was fused to the C- terminus of the knob heavy chain.
  • the glycine-serine linker sequences between the IL2v cytokine and the scFv mask as well as the glycine-serine linker between the VH and VL domains of the scFv mask comprise a protease recognition site for specific unmasking and activation of IL2v by proteases in the tumor micro-environment, e.g. matriptase.
  • the protease recognition site used in P1AI4322 and P1AI4323 was PQARK (Fig.2A-2B), the protease recognition site used in P1AI4324 and P1AI4325 was YAARKGGI (Fig.2C-2D).
  • the four constructs differ in the length of the protease recognition site comprising linker between the IL2v cytokine and the scFv mask, being 38 amino acids in P1AI4322 and P1AI4324 and 25 amino acids in P1AI4323 and P1AI4325.
  • non-cleavable constructs P1AI4646 (with a 38 amino acid linker between the IL2v cytokine and the scFv mask) and P1AI4647 (with a 25 amino acid linker between the IL2v cytokine and the scFv mask) lacking the protease release sites as well as a non-masked construct P1AI4648 were generated (Fig.3A- 3C).
  • P1AI4322, P1AI4323, P1AI4324 and P1AI4325 were produced and purified by WuXi Biologies. In brief, they were transiently transfected into HEK293 and purified by MabSelectSuRe LX protein A affinity chromatography and Superdex200 size-exclusion chromatography. Purification of P1AI4324 involved two additional HiTrap SP HP-1 and SP HP-2 cation exchange chromatography purification steps in between MabSelectSuRe LX protein A affinity chromatography and Superdex200 size-exclusion chromatography.
  • a cleavable (with YAARKGGI sites) and a non-cleavable human PD1 -targeted masked IL2v construct was generated, P1AI4650 and P1AI4651, respectively (Fig.4A-4B).
  • These murine surrogates share the same format as the human constructs but comprise murine sequences to avoid immunogenicity.
  • the V-domains of the PD1 binder correspond to the non-humanized predecessor whereas all constant antibody domain sequences are murine.
  • the only human sequences in these surrogates that could not be avoided are the human IL2v as well as the V- domains of the mask.
  • the murine surrogates were also produced and purified by WuXi Biologies.
  • Affinities of de-immunized MT204 variants (P1AH2050 - P1AH2052, Fig.lA) to human IL2v (SEQ ID NO: 67) were assessed by surface plasmon resonance (SPR).
  • SPR surface plasmon resonance
  • the SPR experiment was performed on a Biacore 8K+ at 25 °C with HBS-EP running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.05 % Surfactant P20, Cytiva, Freiburg/Germany).
  • Anti-PGLALA antibody (M- 1.7.24 mu!gG2b) was directly immobilized on a CM5 chip at pH 5.0 using the standard amine coupling kit (Cytiva, Freiburg/Germany). After activation of the sensor surface with a 1 : 1 mixture of 0.4 M l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and 0.1 M N-hydroxysuccinimide (NHS), 10 ug/ml anti-PGLALA (diluted in 10 mM acetate pH 5.0) was injected for 100 seconds with a flow rate of 10 pl/min. After blocking with 1 M ethanolamine-HCl pH 8.5, the coupling procedure led to approximately 5400 RU anti-PG LAL A surface density.
  • EDC l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
  • NHS N-hydroxysuccinimide
  • De-immunized MT204 variants were captured for 60 s at a flow rate of 10 pl/min with a concentration of 50 nM.
  • Human IL2v G4S avi his was injected at various concentrations (800 - 0.391 nM, 1 :2 dilutions) with a flow of 30 pl / min through the flow cells. Association and dissociation were monitored for 240 s and 1000 s respectively.
  • the chip surface was regenerated after every cycle by using one injection (60 s) of 10 mM glycine pH 2.0. Bulk refractive index differences were corrected by subtracting the response obtained on reference flow cell. Curves were fitted by using the 1 : 1 Langmuir interaction model by using Biacore Insight Evaluation Software 3.0 (Cytiva, Freiburg/Germany) and the results were summarized in Table 1.1.
  • P1AH2050 and P1AH2051 Two of the three de-immunized variants of the anti-IL2v mask, P1AH2050 and P1AH2051, were comparable to the parental anti-IL2v mask P1AF7506 (Fig. IE) in terms of kinetic rate constants and affinities, whereas the third de-immunized variant, P1AH2052, exhibited the fastest off-rate of all of the tested variants and with 995 pM also the lowest affinity.
  • Variant P1AH2051 i.e. hu IgGl GL MT204_VLla - combo VH2 & VH6 PG LAL A, exhibiting the highest affinity of 101 pM, was selected for cloning of the complex masked IL2v formats.
  • Affinities of de-immunized a-PDl binders to human PDl-Fc were assessed by surface plasmon resonance (SPR).
  • SPR experiments were performed either on a Biacore T200 (for P1AH4157 - P1AH4161 and P1AI0356 - P1AI0360) or on a Biacore 8K+ (for P1AI1648 - P1AI1652).
  • P1AH4157 - P1AH4161 and P1AI0356 - P1AI0360 were characterized on a Biacore T200 at 25 °C with HBS-EP running and sample dilution buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.05 % Surfactant P20, Cytiva, Freiburg/Germany).
  • Anti-PGLALA antibody (M- 1.7.24 mu!gG2b) was directly immobilized on a CM5 chip at pH 5.0 using the standard amine coupling kit (Cytiva, Freiburg/Germany). After activation of the sensor surface with a 1 : 1 mixture of 0.4 M l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and 0.1 M N-hydroxysuccinimide (NHS), 20 pg/ml anti-PGLALA (diluted in 10 mM acetate pH 5.0) was injected for 900 s with a flow rate of 5 pl/min. After blocking with 1 M ethanolamine-HCl pH 8.5, the coupling procedure led to more than 12000 RU anti-PG LALA surface density.
  • EDC l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
  • NHS N-hydroxysuccinimide
  • a-PDl binders were captured for 60 s at a flow rate of 10 pl/min with a concentration of 10 nM.
  • Recombinant huPDl-ECD Fc-knob/hole (internal ID P1AD9704) was injected at various concentrations (300- 9,4 nM, 1 : 1 dilution) with a flow of 50 pl / min through the flow cells. Association and dissociation were monitored for 120 s and 600 s respectively.
  • the chip surface was regenerated after every cycle by using injection (35 s each) of 20 mM NaOH. Bulk refractive index differences were corrected by subtracting the response obtained on reference flow cell. Curves were fitted by using the 1 : 1 Langmuir interaction model by using Biacore T200 Evaluation Software 3.1 (GE Healthcare Bio-Sciences) and the results were summarized in the tables below.
  • P1AI1648 - P1AH652 were characterized on a Biacore 8K+ at 25 °C with HBS-EP running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.05 % Surfactant P20, Cytiva, Freiburg/Germany).
  • Anti-PGLALA antibody (M-l.7.24 muIgG2b) was directly immobilized on a Cl chip at pH 5.0 using the standard amine coupling kit (Cytiva, Freiburg/Germany). After activation of the sensor surface with a 1 :1 mixture of 0.4 M l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and 0.1 M N-hydroxysuccinimide (NHS), 20 pg/ml anti-PGLALA (diluted in 10 mM acetate pH 5.0) was injected for 10 min with a flow rate of 10 pl/min. After blocking with 1 M ethanolamine- HCl pH 8.5, the coupling procedure led to approximately 1000 RU anti-PG LALA surface density.
  • EDC l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
  • NHS N-hydroxysuccinimide
  • De-immunized a-PDl binders were captured for 80 s at a flow rate of 10 pl / min with a concentration of 5 nM.
  • Recombinant huPDl-ECD Fc-knob/hole was injected at various concentrations (200 - 0.27 nM, 1 :3 dilution) with a flow of 30 pl / min through the flow cells.
  • Association and dissociation were monitored for 240 s and 800 s respectively.
  • the chip surface was regenerated after every cycle by using two injections (60 s each) of 10 mM glycine pH 2. Bulk refractive index differences were corrected by subtracting the response obtained on reference flow cell.
  • PD1-376 VL2 VH4 The kinetics rate constants and affinity of PD1-376 VL2 VH4 to human PD1 were very similar to the parental humanized antibody P1AA6888 (PD1-0103) with ka 6.40E+05, kd 1.30E-04, and KD 200 pM vs. ka 6.30E+05, kd 1.50E-04, and KD 200 pM, respectively.
  • P1AH4157 (PD1- 376 VL2 VH4) was chosen as preferred de-immunized anti-PDl binder and its V-domain sequences were used for cloning of the complex masked IL2v formats.
  • the PD-1/PD-L1 Blockade reporter assay from Promega is a bioluminescent cell-based assay that can be used to measure the potency of antibodies designed to block the PD-1/PD-L1 interaction.
  • the assay consists in the co-culture of two genetically engineered cell lines: PD-1 T cells as effectors and PD-L1 APC/CHO-K1 cells as target cells.
  • PD-1 effector T cells are Jurkat T cells expressing a human PD-1 and a luciferase reporter gene driven by NF AT response element (NFAT-RE).
  • PD-L1 APC/CHO-K1 target cells are CHO-K1 cells expressing human PD-L1 and an engineered cell surface protein designed to activate cognate TCRs in an antigen-independent manner. When co-cultured, the PD-1/PD-L1 interaction inhibits TCR signaling and downregulates NFAT-RE-mediated luminescence in the effector T cells.
  • the blockade of the PD-1/PD-L1 interaction by anti-PD-1 (or anti-PD-Ll) antibodies releases the inhibitory signal and results in TCR activation of NFAT-RE mediated luminescence.
  • This assay was used to assess the ability of the de-immunized PD-1 binders to block the PD- 1/PD-L1 interaction. For this purpose, eight 1 : 10 dilution steps with 66 nM as the highest concentration of either PD1 IgG PG LALA PDl-IL2v or de-immunized anti-PD-1 were added to the PD-Ll-CHO-expressing cells, right before co-culturing the two cell lines for 5 hours at 37°C. After the 5 hours of incubation, the substrate (BIO-Glo Reagent) was added and the samples were measured at the luminometer (PerkinElmer Reader).
  • Figure 5A and 5B show that PD1-376_VL2_VH1_2_3_4 IgG PG LALA, PD1- 376 VL2 7 VH4 IgG PG LALA and PD1-376 VL2 VH4 IgG PG LALA were approximately as potent as the parental anti-PDl in blocking the PD-1/PD-L1 interaction and overcoming the downstream inhibitory signals.
  • mutations on PD1-376_VL7_VH1_2_4 IgG PG LALA and PD1-376 VL7 VH4 IgG PG LALA result in a decreased potency of 4-5 fold (Table 2.1).
  • PDl-IL2v (as disclosed in WO 2018/184964 Al) and FAP IL2v (as disclosed in WO 2012/107417 Al; INN: Simlukafusp alfa) were used as controls and they showed that the lack of aPD-1 in FAP-IL2v prevents the PD-1/PD-L1 inhibition of TCR signaling and the resulting luminescence.
  • FAP-IL2v as disclosed in WO 2012/107417 Al
  • INN Simlukafusp alfa
  • CD4 T cells were isolated from healthy donor PBMCs with CD4 beads (#130-045-101, Miltenyi) and activated for 3 days in presence of 1 pg/ml plate bound anti-CD3 (overnight pre-coated, clone OKT3, #317326, BioLegend) and 1 pg/ml of soluble anti-CD28 (clone CD28.2, #302934, BioLegend) antibodies to induce T cell activation and PD-1 expression.
  • the cells were washed with PBS to remove unbound molecules. Then, 50 pl of the diluted AF647 anti-PGLALA antibody and Fixable Viability Dye eFluorTM 780 (eBioscience) were added to the cells followed by a washing step after 30 min of incubation at 4°C. Finally, the cells were fixed with BD cell fix (70ul, #340181, BD Biosciences) and acquired at the FACSymphony A3 Cell Analyzer (BD Bioscience). The frequency and MFI of positive cells were determined with FlowJo (VI 0) and plotted with GraphPad Prism.
  • PD1-376_VL2_VH4 IgG PG LALA, PD1- 376 VL2 7 VH4 IgG PG LALA, PD1-376_VL2_VH1_2_3_4 IgG PG LALA and the corresponding parental anti-PDl- and PDl-IL2v bind with similar potency to CD4 T cells.
  • PD1- 376 VL7 VH4 IgG PG LALA and PD1-376_VL7_VH1_2_4 IgG PG LALA show decreased binding to CD4 T cells.
  • FAP-IL2v served as an untargeted control to compare to the effect of IL2v based immunocytokine alone that are not targeted to PD-1.
  • Tables 2.2 and 2.3 show the EC50 of the frequency and MFI of the dose-response binding of the various antibodies to activated CD4 T cells obtained from 2 donors.
  • Table 2.2 EC50 of binding of the dose-response frequency for the selected de-immunized PD-1 on PD-1 + CD4 T cells from healthy donors.
  • CD4 T cells were exposed to allogenic matured DCs to induce the generation of allospecific T cells harboring different antigen-specificities and TCR-affinities.
  • allospecific T cells express immune checkpoints like PD-1 and therefore are useful to measure the functional potency of anti-PDl antibodies as they can unleash T cell effector functions.
  • freshly purified CD4 T cells were co-cultured for 5 days in presence of monocyte-derived allogeneic mature dendritic cells (mDCs).
  • mDCs monocyte-derived allogeneic mature dendritic cells
  • Monocytes were isolated from fresh PBMCs one week before with CD14 beads (130- 050-201, Miltenyi).
  • Immature DCs were generated from the monocytes by culturing them for 5 days in media containing GM-CSF (50 ng/ml) and IL-4 (100 ng/ml).
  • GM-CSF 50 ng/ml
  • IL-4 100 ng/ml
  • TNF-a, IL-ip and IL-6 50 ng/ml each
  • CD4 T cells were enriched via a microbead kit (Miltenyi) from PBMCs obtained from an unrelated donor. Prior to culture, CD4 T cells were labeled with 5pM of Cell Trace Violet (CTV, # C34557, ThermoFisher).
  • CTV Cell Trace Violet
  • CD4 T cells were then plated in flat-bottom 96-well plates together with mature allogeneic-DCs (10: 1 ratio) for 5 days at 37°C, 5% CO2, in presence of a concentration range of purified anti-PDl monoclonal antibodies: PD1-376 VL2 VH4 IgG PG LAL A, PD1-376 VL7 VH4 IgG PG LALA, PD1-376 VL2 7 VH4 IgG PG LALA, PD1-376_VL7_VH1_2_4 IgG PG LALA, PD1- 376_VL2_VH1_2_3_4 IgG PG LALA, parental anti-PDl and PDl-IL2v (50 pl, 1 : 10 dilution steps with the highest concentration of 66 nM). Either no antibody or FAP IL2v was used as a negative control.
  • the anti-PDl monoclonal antibodies promoted T cell secretion of GrzB ( Figures 8 A and 8B) and IFN-y ( Figures 9A and 9B) in a concentration dependent manner. All anti-PD-1 variants were found to enhance granzyme B and IFN y in comparison to FAP-IL2v or untreated cells (negative controls).
  • Tables 2.4 and 2.5 show the EC50 and Area Under the Curve (AUC) of the % of GrzB and IFNy secretion of the dose-dependent response of CD4 T cells to allogenic stimulation and treatment with anti-PD-1 antibody.
  • Table 2.4 EC50 and Area Under the Curve of the dose-response Granzyme B secretion for the selected de-immunized PD-1 on CD4 T cells from healthy donors.
  • Table 2.5 EC50 and Area Under the Curve of the dose-response IFN-y secretion for the selected de-immunized PD-1 on CD4 T cells from healthy donors.
  • the lower EC50 of cytokine production was obtained with the parental anti- PD-1, followed by PD1-376 VL2 VH4 IgG PG LALA.
  • the highest AUC was provided by the de-immunized variant PD1-376 VL2 VH4 IgG PG LALA and the control PDl-IL2v.
  • CHO-huPDl cells (CHO-Kl_MUSMU_PDCDl_Clone_42) were harvested with TrypsinZEDTA, washed with PBS and resuspended in FACS buffer (PBS, 2% FBS, 5 mM EDTA, 0.025% NaN3). Then, 100’000 cells were seeded per well in a round bottom plate. The cells were stained with 30 pl of de-immunized PDl-IgGs, the parental PDl-IgG and the TA PDl-IL2v construct containing the parental PDl-IgG at the indicated concentrations in FACS buffer for 30 min at 4°C.
  • the cells were washed twice with FACS buffer to remove unbound molecules. Then, 30 pl of the diluted PE anti -human Fc specific secondary antibody (1 :50 dilution, 109-116-170, Jackson ImmunoResearch) was added to the cells. After 30 min incubation at 4°C the cells were washed twice with FACS buffer. Finally, the cells were resuspended in 150 pl FACS buffer and measured using a BD Fortessa.
  • NK92 cells were harvested, counted and assessed for viability. Cells were washed three times with PBS to remove residual IL2. The washed NK92 cells were re-suspended in fresh medium (advanced RPMI1640, 2% FCS, 1% Glutamine) without IL2 and 50 pl of the cell suspension containing 10’000 cells were transferred in a 96-well cell culture treated flat bottom plate. First, 25 pl of 0.5 nM FAP-IL2v antibody was added per well. Then, 25 pl of the MT204 antibodies was added per well to reach a final volume of 100 pl per well. The plate was incubated for 3 days in the incubator.
  • the CellTiter-Glo (G7571, Promega) reagents and the cell culture plate were equilibrated to room temperature.
  • the CellTiter-Glo solution was prepared as described in the manufacturer’s instructions and 100 pl of the solution were added to each well. After 10 min of incubation, remaining aggregates were re-suspended by pipetting and 100 pl of the mixture were transferred to a 96 well white flat bottom plate. The luminescence was measured with a Tecan Spark 10M multimode reader.
  • MT204 VL1 and MT204_VLla blocked the IL2v activity comparable to the parental MT204 mask.
  • the MT204_VLlb showed less efficient blocking of the IL2v activity compared to the parental MT204 mask ( Figure 11).
  • CHO-huPDl cells (CHO-Kl_MUSMU_PDCDl_Clone_42) were harvested with Trypsin/EDTA, washed with PBS and resuspended in FACS buffer (PBS, 2% FBS, 5 mM EDTA, 0.025% NaN3). 100’000 cells were seeded per well in a round bottom plate. The cells were stained with 30 pl of the TA PDl-IL2v constructs in FACS buffer for 30 min at 4°C. After the staining, the cells were washed twice with FACS buffer to remove unbound molecules.
  • FACS buffer PBS, 2% FBS, 5 mM EDTA, 0.025% NaN3
  • All four tested constructs contain the de-immunized VL2 VH4 PD1 binder and the MT204 VLla de-immunized mask.
  • All tested TA PDl-IL2v constructs bind comparable to human PD1 on CHO cells ( Figure 12).
  • the NK cell line KHYG-1 was used to test proliferation induction by the TA PDl-IL2v constructs. Cells were harvested, counted and assessed for viability. Cells were washed three times with PBS to remove residual IL2. The washed KHYG-1 cells were re-suspended in fresh medium (advanced RPMI1640, 2% FCS, 1% Glutamine) without IL2 and 12.5 pl of the cell suspension containing 2’000 cells was transferred in a 384-well cell culture treated flat bottom plate.
  • 10 pg of the TA PDl-IL2v constructs were digested with 2 pl Matriptase (Enzo ⁇ 2.5U/pl, ALX-201-246-U25, Lot 08102104 or without Matriptase as undigested control) for 2 hours at 37°C in 20 pl Matriptase buffer (50 mM Tris, 50 mM NaCl, 0.01% Tween 20, pH 9.0) and 12.5 pl of the antibodies were added per well to reach a final volume of 25 pl per well. The plate was incubated for 3 days in the incubator. After 3 days, the CellTiter-Glo (G7571, Promega) reagents and the cell culture plate were equilibrated to room temperature.
  • 2 pl Matriptase Enzo ⁇ 2.5U/pl, ALX-201-246-U25, Lot 08102104 or without Matriptase as undigested control
  • the CellTiter-Glo solution was prepared as described in the manufacturer’s instructions and 25 pl of the solution were added to each well. After 10 min of incubation, remaining aggregates were re-suspended by pipetting and 40 pl of the mixture were transferred to a white flat bottom plate. The luminescence was measured with a Tecan Spark 10M multimode reader.
  • All four tested constructs contained the de-immunized VL2 VH4 PD1 binder and the MT204 VLla de-immunized mask. As controls, the two respective non-cleavable molecules and the nonmasked PDl-IL2v were included. All molecules were tested undigested and upon digestion with recombinant matriptase. After the digestion with matriptase, the TA PDl-IL2v with the PQARK and the YAARKGGI linker regained activity. The activity is slightly reduced compared to the unmasked control most probably due to incomplete cleavage.
  • the murinized TA-PDl-IL2v immuno-conjugates was tested in the mouse fibrosarcoma cell line MCA205, injected subcutaneously into Black 6-huPDl transgenic mice.
  • the MCA205 fibrosarcoma carcinoma cells were originally obtained from Sigma Aldrich (Catalogue Number SCC173) and after expansion deposited in the Roche-Glycart internal cell bank.
  • the tumor cell line was routinely cultured in DMEM containing 10 % FCS (Gibco) at 37 °C in a water-saturated atmosphere at 5% CO2. Passage 11 was used for transplantation, at a viability of 95.3%.
  • IxlO 6 cells per animal were injected subcutaneously in 100 pl of RPMI cell culture medium (Gibco) into the flank of mice using a 1 ml tuberculin syringe (BD Biosciences, Germany).
  • mice Female Black 6-huPDl mice, aged 10-11 weeks at the start of the experiment (bred at Charles Rivers, Lyon, France) were maintained under specific-pathogen-free condition with daily cycles of 12 h light / 12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). The experimental study protocol was reviewed and approved by local government (P 184/2020). After arrival, animals were maintained for one week to get accustomed to the new environment and for observation. Continuous health monitoring was carried out on a regular basis.
  • mice were injected subcutaneously on study day 0 with IxlO 6 of MCA205 cells, randomized and weighed. Ten days after the tumor cell injection (tumor volume > 150 mm 3 ), mice were injected i.v. with TA-PDl-IL-2v YAARKGGI 38mer cleavable linker or TA-PDl-IL-2v 38mer non cleavable linker twice a week for one week. All mice were injected i.v. with 200 pl of the appropriate solution. The mice in the Vehicle group were injected with Histidine Buffer. To obtain the proper amount of immunoconjugate per 200 pl, the stock solutions were diluted with Histidine Buffer when necessary (Table 4).
  • Figure 14 shows that the TA-PD-IL2v YAARKGGI 38mer mediated superior efficacy in terms of tumor growth inhibition compared to vehicle and non-cleavable Mab single agent groups.
  • murine surrogates of PDl-targeted masked IL2v immunoconjugates that target either human (P1AK3638 and P1AK3649) or murine (P1AK3641 and P1AK3640) PD1, were generated.
  • all constant antibody domains in these constructs correspond to murine sequences.
  • the murine surrogates are either targeted to human PD1 for use in humanized mice or human PD1 transgenic mice or murine PD1 for use in syngeneic mouse models with immunocompetent mice. Due to the cross-reactivity of human IL2v to murine IL2 receptors and the lack of cross-reactivity of the scFv mask to murine IL2v, human IL2v has been used in all construct.
  • These murine surrogate constructs bind bivalently to either human or murine PD1 via the N- terminal Fab arms on the Fc DD- and Fc KK+ chains whereas the Fc DD- chain additionally carries a masked (matriptase cleavable or non-matriptase cleavable) C-terminal IL2v.
  • the scFv mask is C-terminally fused ‘in-line’ on the same Fc DD- chain as IL2v.
  • the murine surrogate PDl-targeted masked IL2v immunoconjugates (P1AK3638 and P1AK3649 as well as P1AK3641 and P1AK3640, respectively) have been produced and purified by WuXi Biologies. They were transiently expressed in HEK293 and purified in a 2-column DSP process: 1.
  • Suspension-adapted CHO KI cells (originally received from ATCC and adapted to serum-free growth in suspension culture at evitria) were used for production. The seed was grown in eviGrow medium, a chemically defined, animal-component free, serum-free medium. Cells were transfected with eviFect, evitria’ s custom-made, proprietary transfection reagent, and cells were grown after transfection in eviMake2, an animal-component free, serum-free medium. Supernatant was harvested by centrifugation and subsequent filtration (0.2 pm filter).
  • the IgG was purified using MabSelectTM SuReTM with Dulbecco's PBS (Lonza BE17-512Q) as wash buffer, 0.1 M Glycine pH 3.5 as elution buffer and 1 M Tris HC1 as neutralisation buffer (pH 9). Subsequent size exclusion chromatography was performed on a HiLoad Superdex 200 pg column using the final buffer as running buffer. Dialysis (if needed) was performed using Pierce Slide-A-LyzerTM G2 Dialysis Cassettes with a 2K molecular weight cut off. Antibody concentration (if needed) was performed using Amicon® Ultra Centrifugal Filters with a 30 kDa molecular weight cut off.
  • the concentration was determined by measuring absorption at a wavelength of 280 nm. The extinction coefficient was calculated using a proprietary algorithm at evitria. Purity was determined by analytical size exclusion chromatography with an Agilent AdvanceBio SEC column (300A 2.7 um 7.8 x 300 mm) and DPBS as running buffer at 0.8 ml/min. Endotoxin content was measured with the Charles River Endosafe PTS system.
  • the human FolRl -targeted T cell engager, P1AK1120 (Figure 15), that was used to provide T cell ‘signal 1’ in some of the in vivo efficacy studies, has been produced by evitria AG as described above and purified at Roche in a 3-column DSP process (1. Protein A MabSelectSure, 2. Butyl HP Hydrophobic Interaction Chromatography (HIC), and 3. Superdex200 HiLoad 16/6000 size-exclusion chromatography (SEC)) and formulated into 20 mM Histidine, 140 mM NaCl, pH 6.0. Purity has been determined by SEC-HPLC as well as reduced and non-reduced CE-SDS. The purification batch was tested for a low endotoxin level and the identity of the deglycosylated masses has been confirmed by liquid chromatography-mass spectrometry (LC- MS).
  • LC- MS liquid chromatography-mass spectrometry
  • HEK blue IL2 reporter cell assay with HEK blue IL2 cells overexpressing human PD1 to test activity of murinized TA PDl-IL2v constructs
  • the calculated amount of each molecule was digested with 2 pl recombinant human Matriptase (ALX-201-246-U250, Enzo) and filled up to 20 pl with Matriptase buffer (50 mM Tris, 50 mM NaCl, 0.01% Tween 20, pH 9.0). The corresponding amount of undigested controls was also filled up to 20 pl with Matriptase buffer and treated subsequently in the same way as samples where Matriptase was added. The digest was done for 2 hours at 37 °C. After digestion, the samples were filled up with DMEM + 10% FBS + 1% GlutaMax (assay medium) to have a final starting concentration of 50 nM.
  • HEK-Blue huPDl IL-2 cells (HEK-Blue-IL2_hPDCDl_clone 4) were detached using Cell Dissociation Buffer and re-suspended in DMEM + 10% FBS + 1% GlutaMax (assay medium) at 0.33 Mio cells/ml.
  • 150 pl of HEK-Blue IL-2 cells (containing 50’000 cells) were then seeded in a 96 well flat bottom plate. Then 50 pl of titrated surrogate IL2v molecules were added to each well to reach a final volume of 200 pl per well. The plate was then incubated for 24 hours at 37 °C.
  • HEK blue IL2 reporter cell assay with HEK blue IL2 cells overexpressing mouse PD1 to test activity of murinized TA PDl-IL2v constructs containing a mouse specific PD1 binder.
  • murinized cleavable and non-cleavable TA PDl-IL2v molecules containing a mouse specific PD1 binder in the HEK blue IL2 reporter cell assay using HEK blue IL2 cells expressing mouse PD1.
  • the calculated amount of each molecule was digested with 2 pl recombinant human Matriptase (ALX-201-246-U250, Enzo) and filled up to 20 pl with Matriptase buffer (50 mM Tris, 50 mM NaCl, 0.01% Tween 20, pH 9.0). The corresponding amount of undigested controls was also filled up to 20 pl with Matriptase buffer and treated subsequently in the same way as samples where Matriptase was added. The digest was done for 2 hours at 37 °C. After digestion, the samples were filled up with DMEM + 10% FBS + 1% GlutaMax (assay medium) to have a final starting concentration of 50 nM.
  • HEK-Blue huPDl IL-2 cells HEK-Blue IL-2 cells muPDCDl clone 12 cells
  • DMEM + 10% FBS + 1% GlutaMax assay medium
  • 150 pl of HEK-Blue IL-2 cells were then seeded in a 96 well flat bottom plate.
  • 50 pl of titrated surrogate IL2v molecules were added to each well to reach a final volume of 200 pl per well. The plate was then incubated for 24 hours at 37 °C.
  • the cleavable and the non-cleavable TA PDl-IL2v constructs have both only very limited activity compared to naked PDl-IL2v.
  • the TA PDl-IL2v cleavable constructs have slightly higher activity than the respective non- cleavable constructs that might indicate minor cleavage that can happen during the incubation time ( Figure 19B).
  • TA PDl-IL2v constructs were tested for their capacity to induce proliferation of NK cells and CD8 T cells within PBMCs upon digestion with recombinant human Matriptase.
  • the calculated amount of each molecule was digested with 3 pl recombinant human Matriptase (ALX-201-246-U250, Enzo) and filled up to 20 pl with Matriptase buffer (50 mM Tris, 50 mM NaCl, 0.01% Tween 20, pH 9.0). The digest was done for 2 hours at 37 °C. After digestion, the samples were filled up with RPMI + 10% FBS + 1% GlutaMax (assay medium) to have a final starting concentration of 100 nM.
  • Frozen PBMCs (Biomex) were thawed and immediately re-suspended in prewarmed assay medium. Cells were then centrifuged for 5 min at 350 g and washed once with prewarmed PBS. The CFSE stock solution was diluted 1 :20 with prewarmed PBS to get a working solution with a concentration of 100 pM. 30 Mio cells were resuspended in 30 ml prewarmed PBS. 30 pl of the CFSE working solution was added to the cell suspension and the cells were mixed immediately and incubated for 15 min at 37°C. Then, prewarmed assay medium was added to stop the reaction.
  • the cells were spun down for 10 min at 400 g, resuspended in assay medium and incubated for 30 min at 37°C. After the incubation the cells were washed once with prewarmed assay medium, counted and re-suspended in assay medium at 2 Mio cells per ml.
  • PBMCs were seeded into a 96 well round bottom plate (0.1 Mio cells per well) and the IL2 antibody was added and all wells were filled up to get a final volume of 200 pl. After incubation for 6 days at 37°C, PBMCs were harvested. The cells were centrifuged for 4 min at 400 g and washed once with PBS. Live/dead stain was added in 25 pl PBS diluted 1 : 1000 in PBS) and incubated for 20 min at RT. Afterwards 150 pl FACS Buffer was added and the plate was centrifuged for 4 min at 400g. Supernatant was removed and cells were washed again with 150 pl FACS Buffer.
  • NK cells were defined as CD3 negative and CD56 positive and CD8 T cells were defined as CD3 CD8 double positive.
  • CFSE labeled PBMCs were treated with TA PDl-IL2v molecules containing either a PQARK cleavage site or a YAARKGGI cleavage site and either a 38mer or a 25mer linker.
  • negative control the respective non-cleavable TA PDl-IL2v molecules were included.
  • positive control the respective unmasked PDl-IL2v molecule was included.
  • PBMCs were analyzed by flow cytometry for activation marker upregulation and CFSE dilution was used as an indicator for proliferation.
  • the murinized TA-PDl-IL2v immuno-conjugates was tested in the mouse fibrosarcoma cell line MCA205, injected subcutaneously into Black 6-huPDl transgenic mice.
  • the MCA205 fibrosarcoma carcinoma cells were originally obtained from Sigma Aldrich (Catalogue Number SCC173) and after expansion deposited in the Roche-Glycart internal cell bank.
  • the tumor cell line was routinely cultured in DMEM containing 10 % FCS (Gibco) at 37 °C in a water-saturated atmosphere at 5% CO2. Passage 9 was used for transplantation, at a viability of 97.9%.
  • IxlO 6 cells per animal were injected subcutaneously in 100 pl of RPMI cell culture medium (Gibco) into the flank of mice using a 1 ml tuberculin syringe (BD Biosciences, Germany).
  • mice Female Black 6-huPDl mice, aged 8-10 weeks at the start of the experiment (bred at Charles Rivers, Lyon, France) were maintained under specific-pathogen-free condition with daily cycles of 12 h light / 12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). The experimental study protocol was reviewed and approved by local government (P 184/2020). After arrival, animals were maintained for one week to get accustomed to the new environment and for observation. Continuous health monitoring was carried out on a regular basis.
  • mice were injected subcutaneously on study day 0 with IxlO 6 of MCA205 cells, randomized and weighed. Ten days after the tumor cell injection (tumor volume > 200 mm 3 ), mice were injected i.v. with TA-PDl-IL-2v PQARK 25mer cleavable linker or TA-PDl-IL-2v 25mer non cleavable linker twice a week for one week. All mice were injected i.v. with 200 pl of the appropriate solution. The mice in the Vehicle group were injected with Histidine Buffer. To obtain the proper amount of immunoconjugate per 200 pl, the stock solutions were diluted with Histidine Buffer when necessary.
  • Figure 22 shows that the TA-PD-IL2v PQARK 25mer at both doses tested mediated superior efficacy in terms of tumor growth inhibition compared to vehicle, non-cleavable and Pembrolizumab Mabs single agent groups.
  • the murine surrogtes TA-PDl-IL2v immuno-conjugates was tested in the mouse glioblastoma cell line GL261, injected subcutaneously into Black 6 mice.
  • the GL261 glioblastoma cells were originally obtained from DSMZ (Germany) and after expansion deposited in the Roche-Glycart internal cell bank.
  • the tumor cell line was routinely cultured in DMEM containing 10 % FCS (Gibco) at 37 °C in a water-saturated atmosphere at 5% CO2. Passage 9 was used for transplantation, at a viability of 97.9%.
  • IxlO 6 cells per animal were injected subcutaneously in 100 pl of RPMI cell culture medium (Gibco) into the flank of mice using a 1 ml tuberculin syringe (BD Biosciences, Germany).
  • mice Female Black6 mice, aged 9-11 weeks at the start of the experiment (bred at Charles Rivers, Lyon, France) were maintained under specific-pathogen-free condition with daily cycles of 12 h light / 12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). The experimental study protocol was reviewed and approved by local government (P 184/2020). After arrival, animals were maintained for one week to get accustomed to the new environment and for observation. Continuous health monitoring was carried out on a regular basis.
  • mice were injected subcutaneously on study day 0 with IxlO 6 of GL261 cells, randomized and weighed. Ten days after the tumor cell injection (tumor volume > 100 mm 3 ), mice were injected i.v. with muTA-PDl-IL-2v PQARK 25mer cleavable linker or muPDl-IgG twice a week for one week. All mice were injected i.v. with 200 pl of the appropriate solution. The mice in the Vehicle group were injected with Histidine Buffer. To obtain the proper amount of immune- conjugate per 200 pl, the stock solutions were diluted with Histidine Buffer when necessary.
  • Figure 23 shows that the muTA-PD-IL2v PQARK 25mer at both doses tested mediated superior efficacy in terms of tumor growth inhibition compared to vehicle and muPDl Mabs single agent groups.
  • TA-PDl-IL2v immune-conjugates were tested in combination with FOLR1-TCB bispecific antibody for its anti -turn oral efficacy in a xenograft model.
  • the human TA-PDl-IL2v immune- conjugate was tested in the human breast BC004 patient derived cells subcutaneously injected into humanized NSG mice.
  • BC004 PDX material human breast carcinoma
  • Tumor fragments were digested with Collagenase D and DNase I (Roche, Switzerland), and BC004 cells were used for transplantation.
  • IxlO 6 cells per animal were injected subcutaneously in 100 pl of RPMI cell culture medium (Gibco, Germany) into the flank of mice using a 1 ml tuberculin syringe (BD Biosciences, Germany).
  • Fully humanized NSG female mice (Roche-Glycart, Schlieren, Switzerland) were maintained under specific-pathogen-free condition with daily cycles of 12 h light / 12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). The experimental study protocol was reviewed and approved by local government (ZH184/2020). Continuous health monitoring was carried out on a regular basis.
  • mice were injected subcutaneously on study day 0 with IxlO 6 of BC004 cells, randomized and weighed. Thirty -two days after the tumor cell injection (tumor volume > 150 mm 3 ), mice were injected i.v. with the following immuno-cytokines: TA-PDl-IL2v-PQARK 25mer cleavable 1 mg/kg, PDl-IL2v 0.1 mg/kg and Pembrolizumab 1 mg/kg in combination with FolRl-TCB or Vehicle once a week for four weeks. All mice were injected i.v. with 200 pl of the appropriate solution. The mice in the Vehicle group were injected with Histidine Buffer and the treatment groups with the different constructs.
  • the stock solutions were diluted with Histidine Buffer when necessary. Tumor growth measurements were evaluated with a caliper three times a week and plotted with GrahPad Prism software as volume in mm 3 +/- SEM.
  • Figure 24 shows that the combination FOLR1-TCB 0.3 mg/kg + TA-PDl-IL2v PQARK cleavable linker 1 mg/kg Mabs mediated superior efficacy in terms of tumor growth inhibition compared to FOLR1-TCB + Pembrolizumab 1 mg/kg.
  • the benefit on efficacy showed similar tumor growth inhibition to the combination of FOLR1-TCB 0.3 mg/kg + PDl-IL2v unmasked 0.1 mg/kg Mabs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne d'une manière générale de nouveaux polypeptides d'interleukine-2 (IL-2) activables par une protéase et des immunoconjugués comprenant (i) un polypeptide d'IL-2, (ii) une fraction de masquage et (iii) un lieur comprenant un premier site de clivage de protéase, le lieur ayant une longueur de 20 à 45 acides aminés, la fraction de masquage étant fixée de manière covalente au polypeptide d'IL-2 par l'intermédiaire du lieur, la fraction de masquage étant capable de se lier au polypeptide d'IL-2, dissimulant ainsi de manière réversible le polypeptide d'IL-2, la fraction de masquage comprenant un second site de clivage de protéase, la fraction de masquage ne masquant pas le polypeptide d'IL-2 lors du clivage au niveau du premier et/ou du second site de clivage de protéase. La présente invention concerne également des polynucléotides codant pour de tels polypeptides d'interleukine-2 (IL-2) activables par une protéase et des immunoconjugués, et des vecteurs et des cellules hôtes comprenant de tels polynucléotides. L'invention concerne en outre des procédés de production des polypeptides d'interleukine-2 (IL-2) activables par une protéase et des immunoconjugués selon l'invention, et des procédés d'utilisation de ces polypeptides d'interleukine-2 (IL-2) activables par une protéase et des immunoconjugués dans le traitement d'une maladie.
PCT/EP2023/076655 2022-09-29 2023-09-27 Polypeptides activés par une protéase WO2024068705A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22198666.4 2022-09-29
EP22198666 2022-09-29

Publications (1)

Publication Number Publication Date
WO2024068705A1 true WO2024068705A1 (fr) 2024-04-04

Family

ID=83508938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/076655 WO2024068705A1 (fr) 2022-09-29 2023-09-27 Polypeptides activés par une protéase

Country Status (2)

Country Link
TW (1) TW202430544A (fr)
WO (1) WO2024068705A1 (fr)

Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186567A (en) 1977-04-18 1980-02-05 Hitachi Metals, Ltd. Ornament utilizing rare earth-cobalt magnet
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
WO1993001161A1 (fr) 1991-07-11 1993-01-21 Pfizer Limited Procede de preparation d'intermediaires de sertraline
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5969108A (en) 1990-07-10 1999-10-19 Medical Research Council Methods for producing members of specific binding pairs
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6248516B1 (en) 1988-11-11 2001-06-19 Medical Research Council Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors
US6420548B1 (en) 1999-10-04 2002-07-16 Medicago Inc. Method for regulating transcription of foreign genes
US20030124678A1 (en) 2001-08-13 2003-07-03 University Of Southern California Interleukin-2 mutants with reduced toxicity
US20040132066A1 (en) 2002-02-14 2004-07-08 Kalobios, Inc. Methods for affinity maturation
US6982321B2 (en) 1986-03-27 2006-01-03 Medical Research Council Altered antibodies
US7087409B2 (en) 1997-12-05 2006-08-08 The Scripps Research Institute Humanization of murine antibody
WO2006082515A2 (fr) 2005-02-07 2006-08-10 Glycart Biotechnology Ag Molecules de liaison d'antigenes se liant au recepteur egfr, vecteurs codant pour ces molecules et leurs applications
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2006128690A1 (fr) 2005-06-01 2006-12-07 Micromet Ag Anticorps anti-il2
US20070036752A1 (en) 2001-12-04 2007-02-15 Emd Lexigen Research Center Corp. IL-2 fusion proteins with modulated selectivity
WO2008034473A1 (fr) 2006-09-20 2008-03-27 Dge Dr.-Ing. Günther Engineering Gmbh ProcÉdÉ et dispositif de séparation du méthane et du dioxyde dE carbone dU biogaz
US7527791B2 (en) 2004-03-31 2009-05-05 Genentech, Inc. Humanized anti-TGF-beta antibodies
WO2009061853A2 (fr) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Polypeptides d'interleukine-2 (il-2) mutants
WO2012107417A1 (fr) 2011-02-10 2012-08-16 Roche Glycart Ag Polypeptides d'interleukine-2 mutants
WO2012130831A1 (fr) 2011-03-29 2012-10-04 Roche Glycart Ag Variants de fc d'anticorps
WO2016030350A1 (fr) * 2014-08-29 2016-03-03 F. Hoffmann-La Roche Ag Thérapie combinatoire d'immunocytokines à variant de l'il -2 ciblées thérapie tumorale et d'anticorps anti-pd-l1 humaine
US20170152543A1 (en) * 2015-11-30 2017-06-01 Roche Sequencing Solutions, Inc. System and method for identification of protease substrates
WO2018184964A1 (fr) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugués d'un anticorps anti-pd-1 avec un il-2 mutant ou avec il-15
WO2019222295A1 (fr) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Polypeptides d'interleukine 2 activables et procédés d'utilisation associés
WO2020242884A1 (fr) * 2019-05-24 2020-12-03 Proviva Therapeutics (Hong Kong) Limited Compositions d'il-2 et leurs méthodes d'utilisation
US20210130430A1 (en) * 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2021231278A1 (fr) * 2020-05-11 2021-11-18 F. Hoffmann-La Roche Ag Polythérapie faisant intervenir des pbmc modifiées et un immunoconjugué
WO2022207521A1 (fr) * 2021-03-30 2022-10-06 F. Hoffmann-La Roche Ag Polypeptides activés par une protéase

Patent Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186567A (en) 1977-04-18 1980-02-05 Hitachi Metals, Ltd. Ornament utilizing rare earth-cobalt magnet
US6982321B2 (en) 1986-03-27 2006-01-03 Medical Research Council Altered antibodies
US6248516B1 (en) 1988-11-11 2001-06-19 Medical Research Council Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6417429B1 (en) 1989-10-27 2002-07-09 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5969108A (en) 1990-07-10 1999-10-19 Medical Research Council Methods for producing members of specific binding pairs
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
WO1993001161A1 (fr) 1991-07-11 1993-01-21 Pfizer Limited Procede de preparation d'intermediaires de sertraline
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US7087409B2 (en) 1997-12-05 2006-08-08 The Scripps Research Institute Humanization of murine antibody
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6420548B1 (en) 1999-10-04 2002-07-16 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US20030124678A1 (en) 2001-08-13 2003-07-03 University Of Southern California Interleukin-2 mutants with reduced toxicity
US20070036752A1 (en) 2001-12-04 2007-02-15 Emd Lexigen Research Center Corp. IL-2 fusion proteins with modulated selectivity
US20040132066A1 (en) 2002-02-14 2004-07-08 Kalobios, Inc. Methods for affinity maturation
US7527791B2 (en) 2004-03-31 2009-05-05 Genentech, Inc. Humanized anti-TGF-beta antibodies
WO2006082515A2 (fr) 2005-02-07 2006-08-10 Glycart Biotechnology Ag Molecules de liaison d'antigenes se liant au recepteur egfr, vecteurs codant pour ces molecules et leurs applications
WO2006128690A1 (fr) 2005-06-01 2006-12-07 Micromet Ag Anticorps anti-il2
WO2008034473A1 (fr) 2006-09-20 2008-03-27 Dge Dr.-Ing. Günther Engineering Gmbh ProcÉdÉ et dispositif de séparation du méthane et du dioxyde dE carbone dU biogaz
WO2009061853A2 (fr) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Polypeptides d'interleukine-2 (il-2) mutants
WO2012107417A1 (fr) 2011-02-10 2012-08-16 Roche Glycart Ag Polypeptides d'interleukine-2 mutants
WO2012130831A1 (fr) 2011-03-29 2012-10-04 Roche Glycart Ag Variants de fc d'anticorps
WO2016030350A1 (fr) * 2014-08-29 2016-03-03 F. Hoffmann-La Roche Ag Thérapie combinatoire d'immunocytokines à variant de l'il -2 ciblées thérapie tumorale et d'anticorps anti-pd-l1 humaine
US20170152543A1 (en) * 2015-11-30 2017-06-01 Roche Sequencing Solutions, Inc. System and method for identification of protease substrates
WO2018184964A1 (fr) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugués d'un anticorps anti-pd-1 avec un il-2 mutant ou avec il-15
WO2019222295A1 (fr) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Polypeptides d'interleukine 2 activables et procédés d'utilisation associés
US20210130430A1 (en) * 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2020242884A1 (fr) * 2019-05-24 2020-12-03 Proviva Therapeutics (Hong Kong) Limited Compositions d'il-2 et leurs méthodes d'utilisation
WO2021231278A1 (fr) * 2020-05-11 2021-11-18 F. Hoffmann-La Roche Ag Polythérapie faisant intervenir des pbmc modifiées et un immunoconjugué
WO2022207521A1 (fr) * 2021-03-30 2022-10-06 F. Hoffmann-La Roche Ag Polypeptides activés par une protéase

Non-Patent Citations (60)

* Cited by examiner, † Cited by third party
Title
"Monoclonal Antibody Production Techniques and Applications", 1987, MARCEL DEKKER, INC., pages: 51 - 63
"Remington's Pharmaceutical Sciences", 1990, MACK PRINTING COMPANY, pages: 1289 - 1329
ALMAGROFRANSSON, FRONT BIOSCI, vol. 13, 2008, pages 1619 - 1633
BAZAN, SCIENCE, vol. 257, 1992, pages 410 - 413
BOYMAN ET AL., SCIENCE, vol. 311, 2006, pages 1924 - 27
BRITISH JOURNAL OF CANCER, vol. 120, 2019, pages 3 - 5, Retrieved from the Internet <URL:https://doi.org/10.1038/s41416-018-0294-4>
CHEN ET AL., J MOL BIOL, vol. 293, 1999, pages 865 - 881
CHOTHIA ET AL., J MOL BIOL, vol. 196, 1987, pages 901 - 917
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
DALL'ACQUA ET AL., METHODS, vol. 36, 2005, pages 61 - 68
DATABASE Geneseq [online] 6 January 2022 (2022-01-06), "Anti-PD-1 heavy chain (Fc Knob, LALAPG) - IL-2 variant fusion, SEQ 22.", XP093103530, retrieved from EBI accession no. GSP:BKH11777 Database accession no. BKH11777 *
DATABASE Geneseq [online] 6 January 2022 (2022-01-06), "Anti-PD-1 heavy chain mutant - IL-2 variant fusion protein, SEQ 23.", XP093103532, retrieved from EBI accession no. GSP:BKH11778 Database accession no. BKH11778 *
DATABASE Geneseq [online] 6 January 2022 (2022-01-06), "Anti-PD-1 light chain - IL-2 variant fusion protein, SEQ 25.", XP093103536, retrieved from EBI accession no. GSP:BKH11780 Database accession no. BKH11780 *
DEMETER, A. ET AL.: "Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer.", ANTICANCER RES., vol. 25, 2005, pages 2885 - 2889
DUFFY, M. J.: "Proteases as prognostic markers in cancer.", CLIN. CANCER RES., vol. 2, 1996, pages 613 - 618
FINGL ET AL., THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 1975, pages 1
FONTENOT ET AL., NATURE IMMUNOL, vol. 6, 2005, pages 1171 - 72
GERNGROSS, NAT BIOTECH, vol. 22, 2004, pages 1409 - 1414
GRAHAM ET AL., J GEN VIROL, vol. 36, no. 59, 1977
HEATON, CANCER RES, vol. 53, 1993, pages 2597 - 602
HEELEY, ENDOCR RES, vol. 28, 2002, pages 217 - 229
HOLLINGER ET AL., PROC NATL ACAD SCI USA, vol. 90, 1993, pages 6444 - 6448
HOOGENBOOM ET AL., METHODS IN MOLECULAR BIOLOGY, vol. 178, pages 1 - 37
HU ET AL., BLOOD, vol. 101, 2003, pages 4853 - 4861
HUDSON ET AL., NAT MED, vol. 9, 2003, pages 129 - 134
IMAI ET AL., CANCER SCI, vol. 98, 2007, pages 416 - 23
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
KAMIMURA ET AL., J IMMUNOL, vol. 177, 2006, pages 306 - 14
KINDT ET AL.: "Kuby Immunology", 2007, W.H. FREEMAN AND CO., pages: 91
KLEIN ET AL., ONCOIMMUNOLOGY, vol. 6, no. 3, 2017, pages 1277306
KLIMKA ET AL., BR J CANCER, vol. 83, 2000, pages 252 - 260
KO ET AL., J IMMUNOTHER, vol. 27, 2004, pages 232 - 239
KRIEG ET AL., PROC NAT ACAD SCI USA, vol. 107, 2010, pages 11906 - 11
KRIEG ET AL., PROC NATL ACAD SCI, vol. 107, 2010, pages 11906 - 11
LEBEAU, A. M. ET AL.: "Imaging a functional tumorigenic biomarker in the transformed epithelium.", PROC. NATL. ACAD. SCI. USA, vol. 110, 2013, pages 93 - 98
LI ET AL., NAT BIOTECH, vol. 24, 2006, pages 210 - 215
LILJEBLAD ET AL., GLYCO J, vol. 17, 2000, pages 323 - 329
LONBERG, CURR OPIN IMMUNOL, vol. 20, 2008, pages 450 - 459
LONBERG, NAT BIOTECH, vol. 23, 2005, pages 1117 - 1125
MALEK, ANNU REV IMMUNOL, vol. 26, 2008, pages 453 - 79
MATHER ET AL., ANNALS N.Y. ACAD SCI, vol. 383, 1982, pages 44 - 68
MATHER, BIOL REPROD, vol. 23, 1980, pages 243 - 251
MCCAFFERTY ET AL.: "Nature", vol. 348, 2001, HUMAN PRESS, pages: 552 - 554
MCGOWAN, P. M.DUFFY, M. J.: "Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database.", ANN. ONCOL., vol. 19, 2008, pages 1566 - 1572
MINAMI ET AL., ANNU REV IMMUNOL, vol. 11, 1993, pages 245 - 268
MORRISON ET AL., PROC NATL ACAD SCI, vol. 81, 1984, pages 6851 - 6855
MORRISONOI, ADV IMMUNOL, vol. 44, 1988, pages 65 - 92
OLEJNICZAKKASPRZAK, MED SCI MONIT, vol. 14, 2008, pages 179 - 189
PADLAN, MOL IMMUNOL, vol. 28, 1991, pages 489 - 498
PADLAN, MOLEC IMMUN, vol. 113, no. 3, 1994, pages 169 - 217
PROC NATL ACAD SCI USA, vol. 77, 1980, pages 4216
QUEEN ET AL., PROC NATL ACAD SCI USA, vol. 86, 1989, pages 10029 - 10033
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
SAKAGUCHI, ANNU REV IMMUNOL, vol. 22, 2004, pages 531 - 62
SHANAFELT ET AL., NATURE BIOTECHNOL, vol. 18, 2000, pages 1197 - 1202
VAN DIJKVAN DE WINKEL, CURR OPIN PHARMACOL, vol. 5, 2001, pages 368 - 74
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
VOLKLAND ET AL., MOLECULAR IMMUNOLOGY, vol. 44, 2007, pages 1743 - 1753
WALDMANN, NAT REV IMMUNOL, vol. 6, 2009, pages 595 - 601
YAZAKWU: "Methods in Molecular Biology", vol. 248, 1996, HUMANA PRESS, article "Epitope Mapping Protocols", pages: 255 - 268

Also Published As

Publication number Publication date
TW202430544A (zh) 2024-08-01

Similar Documents

Publication Publication Date Title
US11613587B2 (en) Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists
US20230071733A1 (en) Immunoconjugates
RU2761377C2 (ru) Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
EP3221356B1 (fr) Molécules bispécifiques de liaison à l&#39;antigène activant les lymphocytes t ciblant folr1 et cd3
TWI534155B (zh) 雙特異性ｔ細胞活化抗原結合分子
TWI633121B (zh) 雙特異性活化ｔ細胞之抗原結合分子
TW201815820A (zh) 雙特異性t細胞活化抗原結合分子
EP3820569A1 (fr) Molécules d&#39;anticorps qui se lient à pd-l1 et cd137
TW202115115A (zh) 免疫結合物
EP4314032A1 (fr) Polypeptides activés par une protéase
TW202200609A (zh) 免疫共軛物
KR20230025667A (ko) 프로테아제 활성화된 t 세포 이중특이성 항체
KR20220071264A (ko) 항-pd-l1 항원 결합 단백질 및 이의 응용
US20240376171A1 (en) Protease-activated polypeptides
WO2022148853A1 (fr) Immunoconjugués
WO2024068705A1 (fr) Polypeptides activés par une protéase
US12139553B2 (en) T cell activating bispecific antigen binding molecules
CN115073600A (zh) Gitr结合蛋白及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23776986

Country of ref document: EP

Kind code of ref document: A1